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1 Introduction
1.1 Type 2 diabetes
“The term "diabetes mellitus" describes a metabolic disorder of multiple aetiology 
characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein 
metabolism resulting from defects in insulin secretion, insulin action, or both. The effects of 
diabetes mellitus include long–term damage, dysfunction and failure of various organs”
(World Health Organization 1999). 
Type 2 diabetes is the most common form of diabetes, constituting 90 % of the estimated 382
million diabetes cases worldwide in 2013 (1). It was for a long time known as adult-onset 
diabetes, but in recent years, with increasing prevalence of obesity, also adolescents and even 
children are developing type 2 diabetes, particularly in some ethnic groups (2;3). Type 2 
diabetes is becoming a serious global health problem, especially in countries of low and 
middle income, where the prevalence is increasing the most, and where the age of debut is 
relatively low. The World Health Organization (WHO) estimates that diabetes will be the 7th
most common cause of death by 2030 (4).
The pathogenesis of type 2 diabetes is not fully understood. It is a disease, or probably several 
diseases of multifactorial aetiology. However, we know that development of type 2 diabetes 
requires two major elements: insulin resistance, leading to ineffective insulin action, and ȕ-
cell dysfunction, leading to inappropriate insulin secretion. In this introduction, I will present 
a brief overview of mechanisms known to be involved in the pathogenesis of type 2 diabetes. 
I will also discuss the concept of ethnicity and describe elements that are characteristic of type 
2 diabetes in South Asians, both in their countries of origin and as immigrants to Western 
countries. 
1.1.1 Insulin resistance
Insulin resistance can be described as a reduced biological response to insulin, primarily to its 
acute effects on glucose and lipid metabolism. This is pertinent as whether the insulin is 
produced endogenously or administered exogenously, eventually leading to hyperglycaemia. 
Insulin resistance occurs in several tissues, mainly as decreased insulin dependent glucose 
14
uptake in skeletal muscle, decreased ability of insulin to inhibit lipolysis in adipose tissue, 
impaired insulin mediated inhibition of endogenous glucose production in liver (5) and 
decreased insulin enhanced glucose-induced insulin secretion in pancreas (6). The causes and 
mechanisms of insulin resistance are still unclear, but it is obvious that both type 2 diabetes 
and insulin resistance are closely related to obesity. 
Insulin resistance is also present in several other conditions not directly related to type 2 
diabetes or the metabolic syndrome, both physiological (pregnancy, puberty, stress, old age) 
and pathological (illness, starvation, uraemia, liver cirrhosis) (7).
Insulin sensitivity is a term that is also often used in literature, and it is the reciprocal of 
insulin resistance. Normal limits of insulin sensitivity are wide, often overlapping with some 
pathological conditions. It gives more sense to talk about “normal insulin sensitivity” than 
“normal insulin resistance”. 
NEFA
Non-esterified fatty acids (NEFA) have been shown to play an important role in insulin 
resistance, both in skeletal muscle and in liver (8), and have been suggested as one of several 
possible mechanisms for the development of insulin resistance. NEFA seem to inhibit skeletal 
muscle intracellular insulin signalling pathways, by inhibiting tyrosine phosphorylation of 
insulin receptor substrates (IRS-1 and -2), and IRS-1 and-2 associated phosphatidylinositol 3-
kinase (PI3K) activity (Figure 1). High plasma NEFA concentrations induce a substantial 
increase in intracellular NEFA and its metabolites, such as ceramide and diacyl-glycerol 
(DAG). These in turn activate protein kinase C (PKC) isoforms, again activating other kinases 
like the JUN N-terminal kinase (JNK) and inhibitor of țB kinase (IKK). JNK and IKK, 
through phosphorylation of serine/threonine residues on the insulin receptor and its substrates, 
inhibit insulin signal transduction, thus inhibiting the kinase Akt/protein kinase B (PKB) 
activity. Inhibiting Akt/PKB results in decreased glucose transport by reducing recruitment of 
GLUT4 transporters to the cell membrane, reduced glycogen synthesis, reduced suppression 
of glycogenolysis in liver, reduced protein synthesis and reduced inhibition of lipolysis
(Figure 1) (5). IKK also phosphorylates the inhibitor of kappa B-alpha (IțB-ĮDQLQKLELWRU
of nuclear factor kappa B (NF-țB). This leads to dissociation of IțB-Į from NF-țB, and thus 
NF-țB is free to migrate into the nucleus and promote transcription of proinflammatory 
cytokines (9), as will be viewed in the section on inflammation.
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Figure 1: Insulin signalling pathways
Figure 1: Simplified representation of intracellular insulin signalling in insulin responsive tissues, and 
effect of non-esterified fatty acids (NEFA) and tumour necrosis factor alpha (TNFĮLQDGLSRF\WHV.
Green arrows represent activation, red links represent inhibition. For further explanations, see text. IR: 
insulin receptor, IRS: insulin receptor substrate, TLR: toll-like receptor, PI3K: phosphatidylinositol-3-
kinase, Akt/PKB: Akt/protein kinase B, Glut4: glucose transporter 4, DAG: diacyl-glycerol, PKC: 
protein kinase-C, JNK: JUN N-terminal kinase, IKK: inhibitor of kappa B-kinase, p38MAPK: p38 
MAP-kinase, PKR: double stranded RNA-dependent protein kinase, IțB: inhibitor of kappa B, NFțB: 
nuclear factor kappa B, PTP1B: protein-tyrosine phosphatase 1B. P: phosphorylation. Ad: adipose 
tissue, Li: liver, Pa: pancreas, Mu: muscle, GG: glycogenesis, Prot Ȉ: protein synthesis, Ins. Secr.: 
insulin secretion, GNG: gluconeogenesis, GL: glycogenolysis, Lipogen: lipogenesis, Lipolys: 
lipolysis. (Wium C. 2013).
Inflammation
Adipose tissue and the immune system have common ancestry, both originating from the 
mesoderm, and in more primitive organisms, like the Drosophila, they are one single organ,
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the fat body (10). NF-țB is a group of transcription factors, which plays a pivotal role in 
inflammation. Obesity results in low grade chronic inflammation, by some authors termed 
“metaflammation” (11). Overweight and obese adipose tissue secretes inflammatory markers 
and cytokines/adipokines such as leptin, adiponectin, C-reactive protein (CRP), tumour 
necrosis factor-alpha (TNF-Į), interleukin-6 (IL-6) and interleukin-1ȕ (IL-1ȕ), which have 
been closely linked to insulin resistance. Inflammation increases the infiltration of immune 
cells, mainly macrophages, but also lymphocytes and mast cells, into the adipose tissue, in 
turn contributing to the increasing secretion of cytokines (11).
Macrophages are probably the main source of adipose tissue TNF-Į production (12). TNF-Į
acts in many of the same ways as NEFA, inhibiting the insulin receptor and the intracellular 
signalling pathways through activation of IKK (5). The IKK complex is an important 
serine/threonine kinase, which inhibits the insulin receptor IRS-1 through phosphorylation of 
serine residues, thereby inducing insulin resistance. It also inhibits the IțB-ĮWKURXJK
phosphorylation, so that NF-țB becomes free to move into the nucleus and activate 
inflammatory target genes. TNF-Į in addition inhibits tyrosine phosphorylation of the insulin 
receptor and IRS-1 through activation of protein-tyrosine phosphatase 1B (PTP1B) (5), and 
activates other intracellular serine kinases, like p38 MAP kinase (p38MAPK), JNK and 
double stranded RNA-dependent protein kinase (PKR) (11) (Figure 1). PKR is important in 
pathogen sensing, but is also activated by obesity or infusion of lipids. It stimulates JNK and 
inhibits IRS through serine phosphorylation (13).
Whereas TNF-ĮPDLQO\DFWVORFDOO\LQDSDUDFULQHPDQQHU IL-6 is a pleiotropic, endocrine 
cytokine, with target cells far away from its site of production. IL-6 is produced in a number 
of cells, including both macrophages and adipocytes, and is regarded as both a
proinflammatory and anti-inflammatory cytokine, with effects in many tissues (14). Adipose 
tissue contributes approximately 15-35% of basal circulating IL-6 (15), with visceral adipose 
tissue producing three times more IL-6 than subcutaneous adipose tissue in obese subjects 
(16). It is estimated that10-12 % of this production comes from adipocytes (17). IL-6 is the 
most important circulating factor controlling the acute phase response of the liver (including 
production of CRP, serum Amyloid A, Haptoglobin and others) (18). In the bone marrow, IL-
6 increases platelet production. In vascular endothelium it increases platelet activity, 
expression of adhesion molecules and activates local renin-angiotensin, leading to 
inflammation and damage of the vessel wall (19). In the central nervous system (CNS), 
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secretion of IL-6 from neurones and glial cells, among other effects induces a strong catabolic 
reaction, and also causes reduced food intake and increased energy expenditure (19). IL-6 has 
been shown to be associated with both obesity and type 2 diabetes (20).
CRP is an acute phase reactant that is present in high concentrations in the circulation. It is 
mainly produced by the liver, but also secreted by non-fat cells (immune cells) of the adipose 
tissue (14). CRP has been shown to be increased in obesity (21) and type 2 diabetes (20).
Leptin is a hormone secreted by adipocytes, with an important role in mediating energy 
balance. It acts as a signal to the brain on the status of lipid stores (14). Leptin production is 
higher in subcutaneous than in visceral fat (22). Although the adipocyte is the main site of 
leptin production, low levels of expression have also been detected in placenta, skeletal 
muscle, mammary epithelium and brain (23). When leptin is reduced during fasting, the 
hypothalamus will stimulate appetite and reduce energy expenditure. During famine leptin 
also causes reduction in thyroid hormone production and the reproductive hormonal axis is 
inhibited (24). The immune system is also inhibited (15% of daily energy expenditure is spent 
by the immune system), through direct regulation of T lymphocytes and cytokine production 
(25). When Friedmann and colleagues discovered leptin in 1994, there were initially high 
hopes for a therapeutic effect of leptin on obesity. However, in most subjects with obesity, 
leptin levels are high, and treatment with leptin has not been successful in producing weight 
loss, possibly due to central leptin resistance in obesity (26). Leptin is partly regulated by 
insulin. Low insulin levels decreases leptin, while leptin increases with feeding or in response 
to insulin stimulation (23). Leptin activates AMP-kinase (AMPK) in peripheral tissues like 
muscle, leading to increased fatty acid oxidation. This might be a reason for leptin’s ability to 
improve insulin resistance in subjects with leptin deficiency (27). Leptin also activates other
signalling pathways like MAPK and PI3K in insulin sensitive tissues, overlapping with 
insulin signalling pathways, which may be a mechanism for leptin’s insulin sensitizing 
effects, and may suggest a common pathogenesis of leptin resistance and insulin resistance 
(28).
Adiponectin is an anti-inflammatory signal substance mainly produced in adipose tissue, but 
may also be produced in several other tissues, such as skeletal myocytes, cardio-myocytes and 
endothelium (29). Plasma concentration is high and correlates inversely to white adipose 
tissue, especially visceral adipose tissue. Adiponectin is also strongly correlated with insulin 
sensitivity, with lower adiponectin levels in subjects with type 2 diabetes than in controls, 
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even when matched for BMI (30). Adiponectin exists in the circulation in several isoforms, 
such as trimers, hexamers and multimers of high molecular weight (HMW), where the HMW-
adiponectin is purportedly the most active (31). There is also a globular form, with only the 
C-terminal domain, often trimerised, but lacking the collagen-like side chains. There are two 
main adiponectin receptors, the AdipoR1, AdipoR2. In addition, T-cadherin can also function 
as a receptor for medium and high molecular weight adiponectin (29). It has been shown in 
mouse and human cell cultures that when adiponectin binds to its receptor, it can activate the 
intracellular AMPK signalling cascade, as well as peroxisome proliferator-activated receptor 
(PPAR) Į and p38MAPK. In the liver, activation of PPARĮ in addition to AMPK leads to 
increased fatty acid oxidation and inhibition of fatty acid synthesis (32). Globular adiponectin 
binding to AdipoR1 has been shown to suppress TLR-induced NF-țB activation in mouse 
macrophages (33). Adiponectin also increases the expression of anti-inflammatory cytokines 
like the IL-10 and Interleukin-1 receptor agonist (IL-1RA) in human macrophages (34).
However, in humans, some authors argue that the relationship between adiponectin and 
insulin action is more complex than what has initially been proposed in light of animal 
studies. Adiponectin is often regarded as an insulin sensitizing hormone, whereas some argue 
that currently available evidence rather suggests a role of adiponectin as a downstream signal 
resulting from hyperinsulinaemia, secondary to insulin resistance, and not causing it (31).
This would also explain the higher levels of adiponectin seen in type 1 diabetes. 
The IL-1 cytokine family is large, and plays a central role in immune and inflammatory 
responses. IL-1 consists of two major proteins, IL-1ĮDQGIL-1ȕHQFRGHGE\GLIIHUHQWJHQHV
but structurally related, such that they bind to the same receptors, IL-1RI and IL-1RII.
Binding to IL-1RI induces a potent proinflammatory reaction, with various biological and
metabolic effects, inducing insulin resistance (35). IL-1RII probably acts as a suppressor of 
IL-1 activity by competing for IL-1 binding, acting as a decoy (36). IL-1ȕ maturation is 
regulated by a multi-protein complex called the Nod-like receptor protein 3 (NLRP3) 
inflammasome (37). The IL-1RA also binds to the receptor IL-1RI, inhibiting the intracellular 
response (38). IL-1RA is considered an anti-inflammatory cytokine, that antagonises IL-ȕ
and IL-ĮDQGLVHOHYDWHGDWOHDVWLQSDUWLQUHVSRQVHWR elevation of these inflammatory 
cytokines (17). An early study has showed decreased IL-1RA levels in type 2 diabetes (39),
and it has been demonstrated that lHSWLQGHFUHDVHVȕ-cell production of IL-1RA, down-
regulating IL-5$H[SUHVVLRQLQSDQFUHDWLFȕ-cells in type 2 diabetes (40). However, studies 
that are more recent have shown high levels of IL-1RA in obesity, correlating with BMI, 
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insulin resistance and serum leptin levels. Increased production of IL-1RA in adipose tissue 
has been shown in obese humans (41-43). Subjects with impaired glucose tolerance have 
higher levels of IL-1RA (44), and in two prospective cohort studies, IL-1RA was found to be 
elevated several years before diabetes diagnosis, and significantly predicted incident diabetes 
(45;46). Whether this represents a counteracting mechanism in response to IL-1 is at present 
unclear. IL-1 circulates at much lower levels in plasma and is more difficult to detect in 
clinical samples.
1.1.2 ȕ-cell dysfunction
ȕ-cell dysfunction is a crucial factor in the development of type 2 diabetes. Although serum 
insulin and C-peptide levels can be substantially higher in subjects with type 2 diabetes than 
in healthy subjects, insulin secretion in type 2 diabetes is inadequate to the body’s needs, and 
thus the ȕ-cells are unable to adequately compensate for the increased insulin demand. ȕ-cell 
dysfunction has therefore been recognized as a fundamental component in type 2 diabetes 
(47). It is noteworthy that most of the genetic variants linked to type 2 diabetes actually
concern genes active in ȕ-cells and/or involved in insulin secretion, and only a few are 
involved the processes known to be related to insulin resistance (48). Recent publications, 
however, implicate insulin resistance at the level of the ȕ-cell in the development of ȕ-cell 
dysfunction (6). The ȕ-cell is in fact insulin responsive, with insulin enhancing the glucose-
induced insulin secretion in healthy humans, and this independently of changes in NEFA 
(49;50). In insulin resistant subjects this effect has been shown to be reduced (6).
1.1.3 Glucose and lipid metabolism
Fasting state
In the fasting (post-absorptive) state, endogenous glucose production maintains euglycaemia, 
which is important for the function of several tissues using glucose as their sole source of 
energy. This includes the brain and red blood cells (51). The liver produces approximately 80 
% of endogenous glucose during the post-absorptive state, through glycogenolysis and 
gluconeogenesis. The liver stores approximately 80 grams of glycogen before an overnight 
fast (52). Glycogen reserves can then be degraded into glucose through glycogenolysis. The 
liver also produces glucose through gluconeogenesis, from substrates either issuing from non-
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oxidative glucose degradation, (lactate and pyruvate) or from lipid degradation (glycerol)
(Figure 2). Certain amino acids (alanine) can also be used as substrate (53). The remaining 20 
% of endogenous glucose is produced mainly by gluconeogenesis in the kidneys (51). In the 
post-absorptive state, the body uses lipids as its main source of energy, through fatty acid ȕ-
oxidation. However, approximately 25 % of resting energy expenditure still uses
carbohydrates, where the brain and erythrocytes are responsible for 50 % of glucose 
consumption (54).
In the post-absorptive state, insulin secretion is low due to normal/low levels of plasma 
glucose. Glucagon and other gluco-regulatory hormones, like catecholamines, growth 
hormone, cortisol and thyroid hormone, act to increase endogenous glucose production.
Glucagon increases glycogenolysis and gluconeogenesis in the liver, whereas adrenalin 
mainly increases renal gluconeogenesis. Growth hormone, cortisol and thyroid hormone have 
a more indirect mode of action, with a slower effect, modulating the effects of insulin on 
tissues (51).
Figure 2: Glucose metabolism in liver
Figure 2: Glucose metabolism in liver. Adapted from Radziuk J et al. (53)
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Postprandial state
In the post prandial state, glucose and insulin levels rise, and glucagon levels are reciprocally 
suppressed (51). Insulin facilitates glucose uptake into insulin sensitive tissues like muscle 
and adipose tissue, through increased translocation of the insulin dependent GLUT 4 
transporters to the cell membrane (Figure 1) (55).
In the muscle, insulin inhibits proteolysis and lipolysis, and stimulates glycolysis via 
hexokinase and phosphofructokinase phosphorylation (55). In muscle resting conditions, 
approximately 30 % of the glucose load is removed from the circulation by muscle (51). In 
the muscle, glucose is quickly phosphorylated into glucose-6-phospate, and either broken 
down into tricarboxylic compounds used in the citric acid cycle in the mitochondria for 
energy production (oxidation - less than10 % of the total glucose load), or stored as glycogen 
for later use (less than 20 % of the total glucose load). Insulin activates muscle glycogen 
synthase, stimulating glycogen storage. Muscle glycogen stores are limited, however. After 
repletion of glycogen stores, excess glucose is metabolised through glycolysis into pyruvate, 
alanine and lactate, and then transported back to the liver to be used later as substrate in 
gluconeogenesis and glycogen synthesis. This is termed the Cori cycle/lactic acid cycle, or the 
glucose-alanine cycle (Figure 3) (52).
In adipose tissue, insulin also increases glucose uptake through increased GLUT 4 
translocation. Lipolysis and liberation of NEFA is inhibited, and fatty acid and triacylglycerol 
synthesis is stimulated. Glycolysis is stimulated in the adipose tissue via hexokinase and 
phosphofructokinase phosphorylation, as in muscle. Glucose is then either used as energy 
substrate or metabolised into pyruvate, alanine or lactate which can be released into the 
circulation and transported back to the liver for gluconeogenesis and glycogen synthesis (the 
Cori cycle) (55).
In the liver, the GLUT 2 transporters are not insulin dependent, but are sensitive to plasma 
hyperglycaemia. So is the hepatic glucokinase that phosphorylates glucose into glucose-6-
phosphate inside the hepatocytes. The further steps of polymerisation of glucose for storage as 
glycogen are however hormone dependent. Insulin stimulates glycogen synthase and, together 
with hyperglycaemia, strongly inhibits glycogen phosphorylase (Figure 2). Glucagon and 
adrenaline have an opposite effect to insulin (51). Insulin inhibits gluconeogenesis through 
inhibition of key enzymes in the process. Insulin also inhibits the use of lipids as energy 
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substrate, by activating triglyceride synthesis and by favouring glucose as energy substrate 
instead of NEFA. 
Figure 3: Glucose delivery and metabolism.
Figure 3: Glucose delivery and metabolism in the fasting, post-absorptive state, in the post-prandial 
state and during hyperinsulinaemic clamp. In the post-absorptive state circulating glucose levels are 
maintained by hepatic endogenous glucose production (EGP) through glycogenolysis and 
gluconeogenesis. In peripheral tissues, glucose is oxidized for energy production, or disposed of 
through non-oxidative metabolism, mainly anaerobic glycolysis, resulting in pyruvate, lactate and 
alanine, which are transported back to the liver through the Cori cycle or the glucose-alanine cycle and 
used as substrates for gluconeogenesis. In the post-prandial or clamp state the endogenous glucose 
production is decreased or suppressed, and exogenous glucose from gut absorption or intravenous 
infusion is the main source of circulating glucose. IC: indirect calorimetry. (Wium C. 2013). 
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During clamp hyperinsulinaemia
During the hyperinsulinaemic, euglycaemic clamp, the high physiologic or supra-physiologic 
levels of insulin will have the same effects on the insulin sensitive tissues as in the post-
prandial state previously described. Glucose uptake into muscle is promoted, as well as 
inhibition of hepatic glucose production, through inhibition of both glycogenolysis and 
gluconeogenesis. Inhibition of lipolysis and NEFA liberation from adipose tissue is also seen. 
In healthy subjects with normal insulin sensitivity, clamp hyperinsulinaemia is thought to 
inhibit hepatic glucose production almost entirely, although this is also debated. In subjects 
with type 2 diabetes, with varying levels of insulin resistance, hepatic glucose production is 
variably, and only partly inhibited (56).
1.1.4 Body composition and adipose tissue compartments
Anthropometry
Measuring the body size and composition is important for the evaluation of a person’s risk of 
metabolic disease. Measurements of body height and weight are simple to carry out, and can 
be used to calculate the body mass index (BMI) = ௪௘௜௚௛௧ (௜௡ ௞௚)௛௘௜௚௛௧ (௜௡ ௠)మ , which is widely used to 
diagnose underweight, overweight and obesity, both in research and in clinical practice. 
The WHO has defined BMI cut off points, with underweight BMI < 18.5 kg/m2, normal BMI 
18.5 – 24.9 kg/m2, overweight as BMI 25.0 – 29.9 kg/m2, and obese as BMI > 30.0 kg/m2,
with obese I as BMI 30.0 – 34.9 kg/m2, obese II as BMI 35.0 – 39.9 kg/m2, and obese III as 
BMI > 40.0 kg/m2 (57).
There are ethnic differences in the relationship between BMI values and health risks, where 
Asian and Pacific populations have cut-off points for overweight varying between 22 to 25 
kg/m2. Therefore, the WHO Expert Consultation in 2004 recommended to keep the current 
cut-off points, but adding additional cut-off points at 23.0, 27.5, 32.5 and 37.5 kg/m2 for 
public health actions (58). An Indian consensus statement from 2009 presented revised 
guidelines for the diagnosis of obesity, abdominal obesity and the metabolic syndrome in 
Asian Indians (59). They used the following limits of BMI: normal weight: 18.0 – 22.9, 
overweight: 23.0 – 24.9, obesity:  25.0. 
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Concerning abdominal obesity, the WHO is currently further reviewing available data on the 
relation between waist circumference and morbidity (57). Measurement of waist and hip 
circumference, and the calculation of the waist to hip ratio, and the waist to height ratio have 
often been used, and have shown variable relations to metabolic disease and mortality (60).
The Indian consensus statement from 2009 defined waist circumference cut-offs for obesity 
lower than in the ATP III guidelines (61): in men FPYVFPDQGLQZRPHQ
FPYVFP(62). These new cut-offs were in agreement with the IDF consensus 
worldwide definition of the metabolic syndrome (63) and the “Harmonizing the Metabolic 
Syndrome” joint interim statement from the IDF and several other heart, lung and obesity 
organisations (64).
Bioelectrical impedance analysis
For more direct measurement of fat mass and fat-free mass, the bioelectrical impedance 
analysis is a simple method for assessing body composition, readily available in an outpatient 
clinic, with affordable equipment. BIA measures total body water from given height, 
measured weight and measured impedance, or opposition, to the flow of an electrical current 
sent through the body. It uses built-in software equations for the estimation of fat mass and fat 
free mass in whole body, extremities and trunk (65). There is a variability in hydration and 
density of fat free mass in people of different age, sex and ethnicity, implying a need for using 
equations that have been developed specifically for the population to be studied (65). So far, 
BIA equations have been validated mainly on white populations, although some validated 
equations for other populations exist (66-68). Validations are usually performed against 
isotope dilution (double-labelled water) measurements of body composition or dual energy X-
ray absorptiometry (DXA).
Dual energy X-ray absorptiometry
DXA is a method for measuring total body composition, as well as bone mineral density. Two 
x-ray beams with different energy levels are sent through the whole body, and calculation of 
body composition from differences in absorption is made (65). DXA has the obvious 
advantage of giving estimations of body composition in total and segmental parts of the body 
while exposing the subject to minor amounts of radiation (69). It is more time-consuming 
than BIA, and requires more expensive equipment, but is still relatively easy to use, with low 
25
operational cost, and is much used in both clinical practice and research. A disadvantage to 
DXA, and to BIA, is that they are not capable of discriminating between different abdominal 
adipose tissue compartments. DXA measurements generally have good precision. However, 
the variation in measurements using DXA devices from different manufacturers is large (69).
Computed tomography 
Computed tomography (CT) scans are also used to measure body composition. CT 
measurements have the advantage of giving rapid and accurate analyses of body composition, 
where the different tissue compartments can be assessed (65). Analyses of CT scans are based
on differences in attenuation between various tissues and compartments. Water has an 
attenuation of zero on the Hounsfield scale, whereas air is minus 1000 Hounsfield units (HU) 
and bone is + 400 to + 2000 HU. Muscle has an attenuation of + 10 to + 40 HU, liver is + 40 
to + 60 HU and fat is usually – 100 to – 50 HU. CT is thus capable of discerning different 
tissue compartments, such as adipose tissue compartments, muscle compartments etc., but 
also to assess the degree of ectopic lipid infiltration in tissues, such as the liver or skeletal 
muscle (70;71). A disadvantage with CT is the exposure to radiation with whole body 
measurements (69). A limited number of slices are therefore often performed, providing 
information on regional body composition. 
Liver
When measuring the liver with CT scan, the interest is upon the degree of fatty infiltration. 
This can be assessed by measuring the liver attenuation in unenhanced CT scans, in 
designated regions of interest (ROI). Lower attenuation, signifies higher fat content in the 
liver. The liver attenuation is often compared to the attenuation in the spleen, which is not 
prone to lipid infiltration, and normally has an attenuation a little lower than the liver (around 
+ 50 HU). The liver-spleen ratio (LS-ratio) is normally about 1.2 (72). Measurements using 
three ROI in the liver and two ROI in the spleen of one single slice through the liver at the 
abdominal level (Figure 4A) is said to be optimal and give reproducible results (73).
Subcutaneous abdominal adipose tissue
A CT slice through the mid-abdomen is useful for assessment of the various abdominal 
adipose tissue compartments (Figure 4B). The subcutaneous adipose tissue can be sub-
divided into superficial (SSAT) and deep subcutaneous adipose tissue (DSAT) by the
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superficial fascial plane (74), and studies indicate that there are differences in both the 
structure and function of these two subcutaneous compartments, with DSAT being more 
closely related to insulin resistance, like visceral adipose tissue (VAT) (75). Abdominal 
adipose tissue area on the CT slices will vary according to level of measurement. Choosing 
the best level to measure must take into account the subject’s sex, due to differences between 
male and female anatomy. Shen et al. proposes optimal measuring levels at 5 cm above L4-L5 
in women and 10 to 15 cm above L4-L5 in men (76).
Figure 4: CT measurements of adipose tissue
Figure 4: A) CT slice through liver with steatosis and spleen. Regions of interest (ROI) in green 
circles. B) CT slice through mid-abdomen with green tracings around the superficial and deep 
subcutaneous adipose tissue compartments. C) CT slice through mid-abdomen. Visceral adipose tissue 
(-30 to -190 HU) is highlighted in white. D) Adipose tissue in mid-thigh with green tracings around 
the thigh subcutaneous adipose tissue (TSAT) and the muscle compartment. White arrow points to the 
fascia, which becomes difficult to visualise further along. Green arrows point to inter-muscular 
adipose tissue (IMAT). (Wium C. 2013).
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Visceral abdominal adipose tissue
The VAT (Figure 4C) is situated in the omentum and around the viscera of the intra-
abdominal cavity, and is regarded as the most metabolically active abdominal adipose tissue. 
The amount of VAT has been shown to correlate negatively to insulin sensitivity (75),
positively to inflammation (77) and predispose to non-alcoholic fatty liver disease (78) and 
cardiovascular disease (79).
Adipose tissue in thigh
Adipose tissue in thigh (Figure 4D) can be divided into thigh subcutaneous adipose tissue 
(TSAT), and sub-fascial adipose tissue (SFAT), although the fascia can often be more 
difficult to visualise than in the abdomen. In addition, there is the inter-muscular adipose 
tissue (IMAT). Several studies have demonstrated an inverse relation between thigh 
circumference, TSAT and insulin resistance (80-82), and some, but not all, found a positive 
relation between SFAT, IMAT and insulin resistance.
Magnetic resonance imaging and magnetic resonance spectroscopy 
Magnetic resonance imaging (MRI) is a method for analysing body composition with a high 
degree of accuracy and without any known long-term side effects. This makes it a method of 
choice for whole-body analyses, also in children. MRI gives the possibility to analyse 
regional adipose tissue distribution (83) and also quantify intramuscular adipose tissue (69).
Disadvantages include the need for expensive equipment, the relatively long time of analysis 
in a gantry, which is difficult for people with claustrophobia, and the restricted space. The 
usual diameter of the MRI gantry is 60 – 70 cm, which excludes the examination of the most 
obese patients (65). Magnetic resonance spectroscopy (MRS) can be used as a method to 
discern different chemical entities. Differences in signal intensities can be used to study the 
distribution of metabolites of interest (65), and MRS has also been used to discern intra-
myocellular from extra-myocellular lipid in vivo (70).
28
1.2 Ethnic differences in type 2 diabetes -
Diabetes in South Asians
1.2.1 Ethnicity 
Ethnicity and ethnic groups are concepts that are used extensively in medical research. Race 
was a biological concept that developed in the early 19th century, classifying the human 
population by physical characteristics. Race nowadays has a negative connotation, and 
ethnicity is gradually taking over as classification variable. It has been recognised that the 
genetic and biological variation in racial categorisations is small, making the racial categories 
misleading in indicating variations in health (84;85). Ethnicity is a complex concept, which 
has both socio-cultural and biological components. Ethnicity and ethnic groups are used 
extensively as classifications in studies, but the boundaries between ethnic groups are often 
unclear, and are usually not well defined in medical literature. There is also an ongoing debate 
whether the categorisation into ethnic groups is meaningful or misleading in medical research 
(86;87). Ethnic groups are often categorised through shared origins or social background, 
culture and distinctive traditions, language and religion. The methods used to categorise study 
subjects into ethnicities vary, and can for example be the subject’s reported self-perception of 
ethnicity, ethnicity determined from analysis of names, from country of birth, as well as 
parents’ (or even grand-parents’) country of birth, from observer determined skin colour, or 
from other methods (87;88). European studies often use country of birth or parents’ country 
of birth, whereas studies from the UK and the USA tend to use self-perceived ethnicity. In the 
USA, racial categories, based on the Office of Management and Budget (OMB) classification, 
are also still used (89).
South Asian ethnicity as a concept is arguably an entity that is much too large and 
heterogeneous to be useful in medical research, comprising peoples from several countries, 
with differences in culture, religion and lifestyle. Nevertheless, studies of South Asians in 
their respective countries of origin, and in immigrant populations to Western countries, have 
consistently found increased prevalence of diabetes and cardiovascular disease. The use of 
South Asian ethnicity can therefore be justified, since using this categorisation makes a 
valuable contribution to bringing medical research forward (86).
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1.2.2 Migration
There are two main reasons for migration, the “push factor”, involving negative conditions in 
the country of origin, such as war and poverty, and the “pull factor”, where prospects of a
better life, work opportunities or education draw people to migrate (90). There has been a 
substantial degree of migration from the South Asian region to Western countries over the last 
century, due in large part to the region being a former British colony. It has been observed 
that migration, both from rural to urban areas within South Asia, and to Western countries, 
with urbanisation and westernisation as a result, has led to lifestyle changes. The changes 
including an increase in intake of food high in calories and low in dietary fibre (91) and less 
physical activity (92) has in turn led to an increase in lifestyle related diseases like type 2 
diabetes and cardiovascular disease (90). Psycho-social stress related to migration and low 
socio-economic status might also play a part in development of diabetes and its complications 
(93), although this is not always shown (94).
Norway experienced an increased rate of immigration from Pakistan in the late 1960s, as 
other European countries were closing their borders for non-Western immigration. These 
were labour immigrants, arriving in Norway, mainly in Oslo, in search of work and a better 
future for themselves and their families in Pakistan. Most of these Pakistani immigrants came 
from a small, rural area called Kharian in the Gujrat region of Pakistani Punjab (95). The 
Pakistani immigrants who arrived in the late 1960s and early 70s, until the immigration ban in 
1974, were mainly young men who came to work and earn money to send back home, and 
who planned to return to Pakistan. Many of them nevertheless ended up staying in Norway, 
and were later joined by wives and other family members. Of the more than 32 000 Pakistani 
first and second-generation immigrants in Norway today, many still originate from this 
limited rural area in Gujrat. Eighty-five percent of Pakistani immigrants to Norway live in 
Oslo and Akershus counties. The Pakistani immigrant group is the largest non-Western 
immigrant group in Norway, and the largest overall immigrant group in Oslo (96).
The Sri Lankan immigration to Norway has also taken place over several decades, where 
1987 was the year with the highest number of Sri Lankans arriving in Norway, 1773 persons 
(96), probably due to escalations in the civil war between the Sri Lankan (Singhalese)
government and the Tamil Tigers. In 2012 there were 14 300 Sri Lankans in Norway, making 
the Sri Lankans the 16th largest immigrant group (97). The majority of Sri Lankans in 
Norway are Tamil refugees (96).
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1.2.3 Diabetes in South Asian countries
The main countries of the South Asian region, also called the Indian sub-continent, include 
Pakistan, India, Bangladesh and Sri Lanka. Nepal, Bhutan and the Maldives are also often 
included in this category. This region has one fifth of all diabetes cases in the world (98), with 
diabetes occurring in leaner and younger subjects than in Western countries (99). India was 
until recently the country with the highest total number of subjects with diabetes, now only 
beaten by China (100). A recent review and meta-analysis of the prevalence and trends of 
diabetes in South Asia shows a wide variety in the prevalence, from 3.8 % in rural 
Bangladesh, to 13.9 % in urban India. There is an increasing prevalence trend in all the main 
South Asian countries, with consistently higher prevalence estimates in urban than rural areas 
(101). The current national prevalence rates of diabetes are 8.31 % in India, 6.72 % in 
Pakistan, 9.85 % in Bangladesh and 7.77 % in Sri Lanka (102). According to IDF World 
Atlas, 14.5 % of all adult deaths in the region are attributable to diabetes, with 55 % of these 
deaths occurring before the age of 60 and 27 % before the age of 50 years. Diabetes is hence a 
serious disease also in South Asia, with the second highest mortality rate from diabetes 
worldwide (103).
As important is the high degree of morbidity due to diabetes complications. The increased 
prevalence of diabetes in South Asians is an important reason for the high rates of 
cardiovascular disease (104). Cardiovascular disease (CVD) also occurs at a younger age than 
in Western populations, with a high mortality rate. CVD deaths in the South Asian population 
are predicted to increase from 29 % in 2005 to 36 % in 2030 (105). Micro-vascular 
complications (retinopathy, nephropathy and neuropathy) are linked to poor blood glucose 
control (106). Data are scarce on the prevalence of these complications in South Asia. Studies 
of South Asian immigrants to Western countries find higher rates of these complications as 
well (107;108).
1.2.4 Diabetes in South Asian immigrants to Western 
countries
In the first half of the 1980s, Mather and Keen and their team performed a house-to-house 
survey of all residents in the suburb of Southall in West London. There had been some 
previous reports of high prevalence of diabetes in South Asian immigrants to other parts of 
the world, like South Africa, Fiji, Trinidad and Singapore, but data on prevalence of type 2 
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diabetes in South Asian immigrants to Britain were still lacking. Southall was considered a 
well-integrated, multi-ethnic community, with approximately 66 500 inhabitants, originating 
from Britain, South Asia, East Africa and the Caribbean. Mather and Keen found an age-
adjusted prevalence of diabetes that was at least 3.8 times higher in the group of South Asians 
and East Africans than in Europeans, and a shift towards lower age in the South Asians with 
diabetes compared to the Europeans (109).
This marked the start of many more studies of type 2 diabetes in South Asian immigrants to 
Western countries, both in Europe, America and Australia. The general findings from these 
studies have been that South Asian immigrants develop diabetes at a younger age (109-111),
and at lower BMI(112). They nonetheless have a higher degree of central obesity and lower 
muscle mass (113;114). They have been found to be more insulin resistant (115;116), have 
poorer blood glucose control (117;118) and are more prone to diabetes complications, mainly 
macro-vascular disease, retinopathy, proteinuria and end stage renal disease (119). Numerous 
publications exist regarding diabetes and insulin resistance in South Asians, both in their 
countries of origin and in immigrants to Western countries. However, many of the studies 
have been performed in healthy subjects or subjects with impaired glucose tolerance, and not 
in subjects with established type 2 diabetes. In addition, many studies use surrogate markers 
established from fasting measurements of glucose and insulin. Only a few studies have 
performed euglycaemic clamps to assess insulin resistance, and almost exclusively in healthy 
subjects (115;120-129). The euglycaemic clamp with isotope tracer measurement of 
endogenous glucose production in South Asian subjects with type 2 diabetes has, to this
author’s knowledge, not previously been published. 
1.2.5 Diabetes in South Asian immigrants in Norway
Studies from general practice have shown the same tendencies in Norway as in other Western 
countries, namely higher prevalence of type 2 diabetes in South Asian immigrants, occurring 
at a younger age, and presenting with impaired blood glucose control compared to native 
Norwegians (111;130). Diabetes prevalence has been found to be especially high in women of 
South Asian descent, as high as 26.4 % in Pakistani women and 22.5 % in Sri Lankan women, 
whereas the prevalence in both Sri Lankan and Pakistani men were approximately 20 %. 
Prevalence rates in Norwegians were 2.7 % in women and 6.4 % in men (131). Diabetes in 
this immigrant population is thus becoming an important public health issue also in Norway,
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concerning both diabetes care and prevalence of complications. Tran and co-workers have for 
instance showed a high prevalence of self-reported cardio-vascular disease in ethnic minority 
subjects with diabetes (15.3%) compared to those without diabetes (5.9%) (132).
1.2.6 Proposed theories for the high diabetes prevalence in 
South Asians
Thrifty Genotype
As early as in 1962, Neel proposed the thrifty genotype hypothesis (133). This theory focuses 
on selection of genetic traits favouring energy storage in times of food abundance, for later 
energy reserves during famine, but which become deleterious in times of permanent excessive 
energy intake. It is however still unclear whether results from genetic studies support this 
theory. Recent genetic studies of signals of selection have showed no clear evidence of 
selection of genes linked to type 2 diabetes or obesity. However, signatures of selection of 
protective variants have been found (134;135).
Thrifty Phenotype
The finding that low birth weight was strongly associated with increased risk of type 2 
diabetes and cardiovascular disease in later life (136), especially when later subjected to over-
nutrition (137), lead to the hypothesis of foetal programming and the thrifty phenotype 
hypothesis (136). This hypothesis emphasises the association between poor foetal and infant 
growth, inducing epigenetic modifications, with permanent changes in insulin resistance and 
glucose metabolism, and later development of type 2 diabetes as a result. The hypothesis has 
been challenged by some inconsistencies. For example: The thrifty phenotype should 
facilitate energy saving and storage. However, resting metabolic rate has not been found to be 
consistently lower in people with low birth weight. Regions with cold climate and harsh 
winters, where there were long periods of food shortage, should have made people more 
prone to such foetal programming throughout evolution. Yet people from such regions, like 
the Western Europeans, have been shown to have lower prevalence of insulin resistance 
(138).
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Adipose tissue compartment overflow
The adipose tissue overflow hypothesis (139) proposes the concept that superficial 
subcutaneous adipose tissue is the primary compartment for fat storage, while deep SAT and 
VAT are secondary compartments. The latter compartments are less organized and more 
vascularised than superficial SAT, displaying a higher link to metabolic activity (75;77). In 
the adipose tissue overflow theory, the superficial SAT is less developed in South Asians 
compared to white Westerners, rendering them less tolerant to the accumulation of excess 
energy. With sustained excess energy intake, a subsequent overflow of fat into the deeper 
depots of more metabolically active deep SAT and VAT occurs (139). These deep fat depots 
have higher trans-membrane fluxes of NEFA, releasing lipids into both the systemic and 
portal circulation, and higher secretion of proinflammatory cytokines (5;139). The liver 
receives an increased influx of NEFA, leading to increases in ectopic fat in the liver and 
increased hepatic triglyceride and cholesterol synthesis, again leading to atherogenic 
dyslipidaemia and CVD (139). Increased NEFA in the liver also impairs the inhibition of 
hepatic glycogenolysis by insulin in the post-prandial state, leading to hyperglycaemia 
(9;140). Skeletal muscles also receive an increased influx of NEFA from deep SAT and VAT, 
leading to intra muscular ectopic fat deposition, and increased insulin resistance (9).
Metabolic inflexibility
The metabolic inflexibility theory proposes that the normal switch between high lipid 
oxidation in the fasting state and high glucose oxidation in the post-prandial or clamp 
hyperinsulinaemic states is impaired in type 2 diabetes (141). This leads to less lipids being 
oxidised during fasting, with accumulation of lipids in skeletal muscle as a result, and less 
glucose being oxidised post-prandially, leading to increased plasma glucose values (141). The 
degree of metabolic inflexibility is often measured by the ǻRQ between fasting and 
euglycaemic clamp states. This is however disputed in type 2 diabetes, since the lower ǻRQ is 
mainly determined by the impaired insulin stimulated glucose disposal rate, and not glucose 
oxidation (142).
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Mitochondrial efficiency
The mitochondrial efficiency hypothesis proposes that South Asians have more tightly 
coupled mitochondria than Europeans have. This leads to less heat production and higher 
energy producing efficiency in the mitochondria, thus higher energy conservation and the 
possibility of weight gain (143). The respiratory chain in mitochondria, where oxidation 
transforms fuel substrates into energy in the form of ATP, is regulated by energy demand, 
such that when ADP is not available for phosphorylation, protons cannot enter the 
mitochondrial matrix through ATP synthase. However, this coupling of substrate oxidation to 
ATP synthesis is imperfect, with evidence of proton leaks, due to uncoupling proteins (UCP).
This proton leak leads to energy dissipation as heat, and thus increased energy expenditure. 
This could further impact on body weight (144). Uncoupling proteins are members of an 
anion carrier protein family located in the inner mitochondrial membrane. They reduce 
metabolic efficiency by promoting net proton translocation from the inter-membrane space 
into the mitochondrial matrix. The potential energy available for ATP synthesis is thereby 
reduced (145). UCP1 is mainly expressed in brown adipose tissue. UCP2, however, is 
expressed in many tissues, while UCP3 is mainly expressed in skeletal muscle. Recent studies 
have indicated that UCP2 and 3 gene polymorphisms may be associated with obesity, 
metabolic syndrome and type 2 diabetes in Asian Indians (146-148). A meta-analysis by de 
Souza et al. published this year also found that the association between some UCP2 and 3 
gene polymorphisms and type 2 diabetes was only significant in Asians, and not in people of 
European ancestry (145). Over-expression of UCP2 has moreover been shown to inhibit 
glucose-stimulated insulin secretion in rat ȕ-cells and in INS-1 ȕ-cells, through reduced ATP 
levels, thus providing another link with type 2 diabetes (149).
Others
The variable disease selection hypothesis explains the increased visceral adipose tissue in 
South Asians by the need for meeting immediate energy demands by the immune system in 
the gut in situations of gastrointestinal infections (150). Lipid stores that are readily available 
in the proximity of the gut would therefore be an advantage in areas of endemic 
gastrointestinal diseases like cholera.
Watve and Yajnik (138) a few years back proposed the behavioural switch hypothesis. This 
hypothesis consists of a socio-ecological adaptation in South Asians, which induced two 
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transitions: 1) the transition from “r” to “K”, where “r” is the strategy of producing a large 
number of offspring, investing little in each, and “K” is a strategy where fewer offspring is 
produced, but more is invested in each. For example, insulin resistance in pregnant mothers 
increases the foetal weight, which constitutes an increase of the “investment” in the offspring. 
2) The soldier to diplomat transition, where a shift from muscle dependent to brain dependent 
strategies is advantageous with the advent of more structured societies. Insulin resistance also 
favours glucose availability for the brain of the diplomat, rather than the muscles of the 
soldier. 
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2 Aims
2.1 General aim
The general aim of this study was to explore differences in the pathophysiology of type 2 
diabetes in South Asian immigrants to Norway, as compared to Norwegian or Nordic subjects 
with type 2 diabetes. Better knowledge of the pathophysiology of type 2 diabetes in South 
Asians in Norway is necessary to develop prevention and treatment strategies that are more 
efficient.
2.2 Specific aims
To study possible differences between Nordic and South Asian subjects with type 2 diabetes
in: 
1. insulin sensitivity, through low and high euglycaemic clamp insulin infusions, and by 
estimation of endogenous glucose production through the tracer dilution method 
(papers I and III).
2. anthropometrics and body composition (papers I and II).
3. adipokines and inflammation markers and their relation to insulin sensitivity and body 
composition (papers I and II).
4. ȕ-cell function, through measurement of first-phase insulin secretion during an intra-
venous glucose tolerance test (paper III).
5. glucose and lipid metabolism, both in the basal post-absorptive state and during clamp 
hyperinsulinaemia (paper III).
37
3 Subjects and Methods
3.1 Patients and design
This thesis is built on results from two clinical studies performed at the Diabetes Research 
Laboratory, Aker/Oslo University Hospital during the years 2003-2012. The first study, the 
Diabetes In Pakistani Immigrants (DIPI) project, was a cross-sectional study of Norwegian 
and Pakistani subjects with type 2 diabetes, where results are presented in papers I and II. The 
second study, the Diabetes Intervention trial with Vitamin D in subjects of sub-Indian and 
Nordic Ethnicity (DIVINE) study, was a randomized, controlled intervention trial, which 
recruited Nordic and South Asian subjects with type 2 diabetes and hypovitaminosis D. 
Results from the baseline examinations of these subjects are reported in paper III of this 
thesis.
3.1.1 The Diabetes In Pakistani Immigrants (DIPI) project
Design
This was a cross-sectional study comparing young subjects with type 2 diabetes from two 
different ethnic groups, Pakistanis immigrants and Norwegians, all living in the Oslo area. 
Subjects
We recruited Norwegian and Pakistani patients with type 2 diabetes, aged 45 years or 
younger. Inclusion criteria were: confirmed type 2 diabetes, subjects of Norwegian or 
Pakistani origin, age 18 – 45 years, on any type of anti-hyperglycaemic treatment. Exclusion 
criteria were: ethnicities other than Norwegian or Pakistani, positive test for anti-GAD or anti-
IA2 autoantibodies, age > 45 years, person unwilling or unable to give informed consent. We 
included 19 Pakistani and 21 Norwegian sex-matched patients (age 29-45 years, 49 % men). 
All Pakistani participants were first generation immigrants. One Pakistani woman was 
excluded on the first day of testing, because of difficulties in obtaining intravenous access. 
The remaining 39 patients were examined, where median (IQR) age for the Pakistani and 
Norwegian subjects were 41 (8) and 42 (6) years respectively, and diabetes duration was 9 (7) 
and 5 (9) years respectively.
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3.1.2 The Diabetes Intervention trial with Vitamin D in subjects
of sub-Indian and Nordic Ethnicity (DIVINE) project
Design
The data used in this paper are also cross-sectional, from the baseline data of a randomized 
controlled intervention trial, designed to investigate the effect of high dose vitamin D 
supplementation to type 2 diabetic subjects with concomitant vitamin D deficiency or 
insufficiency. The power estimations were done for the purpose of the intervention trial. 
Subjects
Sixty-two patients with type 2 diabetes and vitamin D deficiency or insufficiency, of Nordic 
or South Asian ethnicity, were recruited from our outpatient clinic, from general practice, 
from advertising by posters in the hospital lobby and at pharmacies in the region, and from 
advertisements in local newspapers. Men and women from the Oslo area, above 18 years of 
age, of Nordic or South Asian origin, were eligible, regardless of type of anti-diabetic 
treatment. 190 patients were screened, 62 patients were recruited, and 61 patients were 
subjected to initial intra-venous glucose tolerance tests (IVGTT) and clamp procedures. One 
of the 62 patients had to be excluded due to severe difficulties in getting the two intravenous 
catheters in place. The cohort thus consisted of 42 Nordic (65 % men) and 19 South Asian (47 
% men) subjects with a mean age of 58.3 ± 8.3 and 49.7 ± 9.4 years respectively, and with a 
mean diabetes duration of 9.6 ± 7.0 and 9.3 ± 5.4 years. 
3.2 Methods
3.2.1 Pre-examination preparations
To create standardised conditions for the clamp examinations, patients in both studies were 
asked to stop oral anti-diabetic drugs for two days, and insulin for at least 12 hours prior to 
examination (long-acting insulin analogues for at least 24 hours). Patients were also asked to 
refrain from strenuous physical exercise and alcohol intake during these two days, and to 
arrive fasting, including no tobacco, for at least 10 hours, from the night before the 
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examination. All clamp and IVGTT examinations were performed at the Diabetes Research 
Laboratory, Oslo University Hospital. 
CT measurements in the DIPI-study were performed on a separate day, at the Department of 
Radiology, Aker University Hospital. The patients had that day eaten a light breakfast 
between 7.30 and 8.00, and the CT scan was performed at approximately 10.00. 
DXA and anthropometrical measurements in the DIVINE study were also performed on a 
separate day, with DXA measurements at the Bone Laboratory at the Endocrine Outpatient 
Clinic, Aker, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo 
University Hospital. The patients had been asked not to eat or drink for at least 2 hours before 
arriving for the examinations. 
3.2.2 Anthropometrical measurements
Height to the nearest 0.1 cm and weight to the nearest 0.1 kg were measured with participants 
wearing light clothing and no shoes. Waist and hip circumferences were assessed with a tape 
measure with spring scale to ensure equal traction at every measurement, measuring at mid-
point between the lowest rib margin and the iliac crest, and at the level of the major 
trochanter, respectively, with subjects standing upright, legs together. BMI was calculated as 
ௐ௘௜௚௛௧ (௞௚)
ு௘௜௚௛௧మ(௠) . WHR was calculated as waist circumference/hip circumference. 
3.2.3 Bioelectrical Impedance Analysis
BIA was performed on a Tanita Body Composition Analyser BC-418 MA (Tokyo, Japan), 
providing measurements of percentage total body fat, body fat mass in kilograms and fat free 
mass in kilograms. All subjects were fasting and voided urine before measurement. The 
standard software algorithm provided by the manufacturer was used for all patients, 
regardless of ethnicity. 
3.2.4 Dual X-ray Absorptiometry
A Lunar Prodigy from GE Healthcare was used for measurement of body composition by dual 
x-ray absorptiometry, where total fat mass in kg, percentage total body fat and fat free body 
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mass in kg were measured. Here also, the standard software algorithm provided by the 
manufacturer was used for all patients, regardless of ethnicity. 
3.2.5 CT measurements of adipose tissue compartments
CT measurements of adipose tissue and muscle compartments in the abdomen and thigh were 
performed using Somatom (Erlangen, Germany) with the patient examined in a supine 
position, arms extended above the head. Three single axial scans were performed through:
i) the liver and the spleen, at the level of Th12.
ii) the mid-abdomen, 10 cm above L4/L5 in men and 5 cm above L4/L5 in women.
iii) the thighs, at mid-distance between the anterior-superior iliac spine and the upper margin 
of the patella. 
The fat content of the liver was based on attenuation values in Hounsfield Units (HU). The 
liver-spleen ratio (LS-ratio) was calculated based on the mean of measurements within three 
regions of interest (ROI), in the liver (two in the right lobe and one in the left lobe), and two 
ROI measurements in the spleen, each ROI measuring 80 mm2 (Figure 4A). In mid-abdomen, 
the circumferences were tracked for the superficial and deep subcutaneous adipose tissue 
compartments, divided by the superficial fascial plane (Figure 4B) (74). The visceral adipose 
tissue compartment was measured by tracking the inner abdominal circumference, and 
highlighting the pixels below -30 and above -190 HU in order to quantify only the adipose 
tissue (Figure 4C).
The right thigh was selected for measuring thigh muscle and superficial adipose tissue 
compartments. A mark was made on the subject’s thigh at mid-distance between the anterior-
superior iliac process and the cranial edge of the patella before examination, to determine the 
level of the thigh slice. Because of difficulties in tracking the fascia in the thigh, only 
subcutaneous fat area and muscle area was measured (Figure 4D).
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3.2.6 Laboratory measurements
All fasting and non-fasting blood samples from patients were collected from a catheter placed 
in an elbow vein after an overnight fast. 
Fasting plasma glucose was measured immediately at the Diabetes Research Laboratory by 
the glucose oxidase method. For Paper I and II a Glucose Analyser II (Beckman Instruments) 
was used, and for Paper III a YSI 2300 (Yellow Springs, OH, USA) was used. On the YSI 
2300 whole blood glucose was measured and plasma glucose was calculated with the 
following equation: whole blood glucose x 1.119, modified from (151). This equation is valid 
when erythrocyte volume fraction (EVF) is within normal limits.
Serum insulin was collected both fasting and throughout the examinations. After at least 20 
minutes coagulation time, the samples were centrifuged and serum separated from blood cells. 
The samples were then kept refrigerated until analysis. For Papers I and II the 
radioimmunoassay (RIA) kit, formerly from Linco Research, presently available from 
Millipore Corp. (Billerica, MA, USA) was used, and for Paper III, both serum insulin and C-
peptide were measured using an immuno-fluorometric assay (DELFIA) from Perkin Elmer 
Life Sciences (Wallac Oy, Turku, Finland). Serum was also collected in the same way, and 
stored at - 80°C for later 25-hydroxyvitamin D measurements on radioimmunoassay (RIA) 
kits from DiaSorin (Stillwater, MN, USA). These analyses were all performed at the Hormone 
Laboratory, Oslo University Hospital.
Lithium-heparin tubes were used for collection of plasma for lipid and transaminase analysis. 
After immediate centrifugation, the tubes were sent to the Department of Clinical Chemistry 
for same day analysis. Fasting plasma total cholesterol, HDL cholesterol, triglycerides, ASAT 
and ALAT were measured using a routine enzymatic method (Roche Diagnostics, Mannheim, 
Germany). Plasma LDL cholesterol was calculated using the Friedewald equation (152).
EDTA whole blood was collected for same day HbA1c analysis at the Department of Clinical 
Chemistry, by high performance liquid chromatography. For results reported in Papers I and 
II the analyses were performed on a Variant analyser (Bio-Rad, Richmond, CA, USA), and 
for Paper III on a Tosoh G7 analyser (Tosoh Corp., Tokyo, Japan).
EDTA whole blood was also collected for EVF automatic estimation on a Sysmex XE-2100/-
5000 (Sysmex Corp., Kobe, Japan), at the Department of Clinical Chemistry.
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EDTA-plasma was collected, centrifuged and immediately frozen at – 20°C, and then later in 
the day transferred to a - 80°C freezer. Plasma for NEFA measurements were collected on 
chilled EDTA-tubes. NEFA were analysed using a NEFA C enzymatic colour test kit, (Wako 
Chemicals GmbH, Neuss, Germany), modified to run on a Technicon RA1000 (Technicon 
Instruments Corp., Tarrytown, NY, USA), at the Department of Nutrition, Institute of Basic 
Medical Sciences, University of Oslo.
Plasma levels of adiponectin and leptin were analysed at the Hormone Laboratory using RIA 
kits from Millipore Corp. (Billerica, MA, USA),(also formerly from Linco Research). 
At the Research Institute of Internal Medicine, the plasma high sensitive C-reactive protein 
(hsCRP) was measured using a DuoSet ELISA kit from R&D Systems (Minneapolis, MN,
USA). Plasma interleukin-1 receptor antagonist (IL-1RA) was measured using CytoSet from 
Invitrogen Corporation (Carlsbad, CA, USA), with streptavidin-horseradish peroxidase from 
R&D Systems. Plasma measurement of interleukin-6 (IL-6) was performed using a High 
Sensitivity ELISA kit from Abcam plc. (Cambridge, UK). 
Plasma for [6,6-2H2]-glucose analysis was collected on Fluoride Oxalate tubes, immediately 
centrifuged, separated from blood cells and frozen at – 80°C for later analysis. The [6,6-2H2]-
glucose was measured by LC-MS/MS, via turbulent flow chromatography (Cohesive 
technologies RXT1, Franklin, MA, USA), combined with a tandem mass spectrometry (Sciex 
API3000, Applied Biosystems, Foster City, CA, USA), at the Clinical Metabolomics Core 
Facility, (Rigshospitalet, Copenhagen, Denmark).
Urine produced throughout basal equilibration, IVGTT and clamp examinations was collected 
until the end of the clamp and analysed for urea using an enzymatic-kinetic UV assay on a 
Roche Modular P analyser (Roche Diagnostic, Basel, Switzerland) at the Department of 
Clinical Chemistry, Aker, Oslo University Hospital. 
3.2.7 Two-step euglycaemic clamp
For the DIPI-study, we performed a euglycaemic, hyperinsulinaemic clamp with two steps, 
first administering an insulin dose of 40 mU/m2/min for a minimum of 100 minutes, until at 
least 30 minutes of stable euglycaemia was obtained. This was directly followed by a 400 
mU/m2/min insulin infusion, also for a minimum of 100 minutes, with at least 30 minutes of 
stable euglycaemia at the end. This gave us euglycaemic clamp measurements with serum 
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insulin levels both at physiological and at supra-physiological levels. The high-level insulin 
infusion was included to assure total suppression of endogenous glucose production during 
clamp.
7KHJOXFRVHLQIXVLRQUDWHLQȝPROP2/min was established, and denoted GIR40 and GIR400
respectively. Because of varying metabolic clearance rates of insulin, the insulin levels, given 
as the mean of three measurements at ten-minute intervals at the end of each step of the 
clamp, differed between patients. The insulin sensitivity index was therefore also calculated, 
and expressed as the ratio of the GIR to the prevailing mean serum insulin levels ((GIR/I) x
100), denoted ISI40 and ISI400.
Every 30 minutes during the two-step euglycaemic clamp, EDTA plasma for non-esterified 
fatty acid (NEFA) measurements was extracted (Figure 5).
Figure 5: The DIPI clamp study
3.2.8 Single step euglycaemic clamp with stable isotope tracer 
For the DIVINE-study, we used a single insulin infusion rate, at high-physiological levels, but 
we also measured the endogenous glucose production, both in the basal, fasting state and 
during clamp stable euglycaemia. Estimation of endogenous glucose production was 
performed using the stable isotope dilution method. The stable isotope [6,6-2H2] glucose was 
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chosen in order to avoid tracer contamination, and because it was non-radioactive, and thus 
easier to handle and would not present an obstacle in patient recruitment. The [6,6-2H2]
glucose also is only moderately recycled, in the Cori (lactic acid) and glucose-alanine cycles 
between muscle and liver, mostly in the basal, post-absorptive state. Estimations of basal 
endogenous glucose production is therefore reliable, but includes some gluconeogenesis from 
the Cori cycle, especially in obese type 2 diabetic patients, where this recycling increases total 
glucose disposal (TGD) approximately 25 % above normal values (52). In the DIVINE-study, 
all patients had type 2 diabetes and most were obese.
Pre-examination, baseline plasma samples were collected for correction for background [6,6-
2H2] glucose content. A primed (170 mg) continuous (1.7 mg x min-1) infusion of [6,6-2H2]
glucose (Cambridge Isotope Laboratories, Inc., Andover , MA) was initiated in the morning 
of the examination day, and maintained throughout the experiment. At the end of a 2-hour 
stabilisation period, collections of three plasma samples at 10-minute intervals were made for 
measurement of basal endogenous glucose production. At the end of the 2 ½ hour long 
euglycaemic clamp, another three plasma samples were collected at 10-minute intervals for 
measurement of clamp endogenous glucose production (Figure 6).
Calculations of endogenous glucose production (EGP) at the end of the basal equilibration 
period and during clamp euglycaemia were performed. Both were performed during steady 
state for plasma glucose, with only small variations in glucose concentration and tracer 
enrichment over time. Thus steady state equations, where rate of appearance equals rate of 
disappearance, have been applied for the calculation of both EGP and total glucose disposal 
(153;154). EGP in the basal state was calculated as follows:
ܧܩ ௕ܲ௔௦௔௟ = (
ܧ௜
ܧ௣(௕௔௦௔௟) െ 1)ܫ
where I is the rate of [6,6-2H2]-glucose infusion (μmol/m2/min), Ei is the enrichment of the 
tracer infusion in moles percent excess (mpe) and Ep(basal) is the mean [6,6-2H2]-glucose 
enrichment in plasma (mpe) at the end of the basal stabilisation period. At the end of the 
euglycaemic clamp, TGD was calculated as follows:
ܶܩܦ = ܫ × ܧ௜ + ܩܫܴ ×  ܧ௠ܧ௣(௖௟௔௠௣) െ ܫ
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where GIR is the exogenous glucose infusion rate (μmol/m2/min), Em is the [6,6-2H2]-glucose 
enrichment (mpe) in the infused glucose, and Ep(clamp) is the mean [6,6-2H2]-glucose 
enrichment (mpe) in the plasma samples taken during the last 30 minutes of the clamp 
euglycaemia. The EGP during clamp euglycaemia, EGPclamp =TGD – GIR. Between subject 
and within subject coefficients of variation for plasma glucose levels in clamp steady state 
were 10.0 % and 4.6 % respectively. 
3.2.9 IVGTT
After a 2-hour tracer equilibration period, the IVGTT was performed, with a < 1-minute 
intravenous bolus injection of glucose 500 mg/ml, 0.3 g/kg body weight. Blood samples were 
drawn for plasma glucose concentration as well as serum insulin and C-peptide determination 
at -2, 0, 2, 4, 6, 8, 10, 15 and 30 minutes after glucose bolus injection. 
The first phase insulin secretion/Acute Insulin Response to glucose (AIRg) was calculated as 
the incremental area under the curve (AUC) for insulin from time 0-8 minutes and 0-30
minutes.
3.2.10 Euglycaemic clamp with tracer 
Immediately following the IVGTT, a euglycaemic, hyperinsulinaemic clamp was performed 
as described in paper III. Insulin was infused at a rate of 80 mU/m2/min, after an initial bolus
and 10 minute priming infusion determined by the patients pre-clamp plasma glucose. The 
infusion was maintained for 2 ½ hours or more, until at least 30 minutes of stable 
euglycaemia was obtained. When plasma glucose had decreased to euglycaemic values, a
variable infusion of glucose 200 mg/ml enriched with 8 mg x g-1 glucose of [6,6-2H2]-glucose 
was continually adjusted to maintain euglycaemia.
Plasma glucose was regularly measured on a Precision Xceed glucometer (Abbott 
Laboratories. Abbott Park, IL), with five-minute intervals when the patient approached 
euglycaemia. Control measurements at least every 30 minutes, and every 10 minutes during 
the last 20 minutes of the clamp, were performed on a Y.S.I 2300 STAT analyser. The 
glucose infusion rate (GIRLQȝPRONJ))0PLQZDVHVWDEOLVKHG
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3.2.11 Indirect Calorimetry
Indirect calorimetry measures O2 uptake from inspired air and CO2 excretion to expired air, 
and together with urinary nitrogen losses (measured as urinary urea) enables us to estimate the 
rate of oxidation of carbohydrates, lipids, and proteins, and measure basal and clamp-
hyperinsulinaemic energy expenditure. Together with clamp measurements of total glucose 
disposal, this gives us information about glucose oxidation and non-oxidative glucose 
metabolism, as well as lipid oxidation, in both the fasting and clamp hyperinsulinaemic state. 
Indirect calorimetry was performed using a Jaeger Oxycon Pro (Erich Jaeger, Viasys 
Healthcare, Germany), a computerized flow-through canopy gas analyser system. During a 
40-minute period at the end of the basal tracer equilibration period and at the end of the 
euglycaemic clamp, the canopy hood was placed over the patient’s head. After a ten-minute 
adaptation period, the expired and inspired air was continuously sampled and analysed for O2
and CO2 content during a 30-minute steady state period. Whole body substrate oxidation was 
estimated from the mean values of VO2 and VCO2 measured, and from measurement of 
urinary nitrogen (urea). Average basal and insulin stimulated glucose and lipid oxidation rates 
were calculated using Frayn’s equations (155). Non-oxidative glucose metabolism was 
calculated as the difference between total body glucose utilization (as determined by the 
euglycaemic clamp with tracer dilution method) and the rate of glucose oxidation (as 
determined by indirect calorimetry).
Figure 6: The DIVINE IVGTT and euglycaemic clamp 
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3.2.12 Statistical analyses
Data are presented as mean ± standard deviation or median (inter-quartile range) unless 
otherwise specified. We analysed non-normally distributed data log-transformed, or using 
non-parametric methods, as appropriate. Student’s t tests or Mann Whitney U tests were used 
for comparison of continuous variables between groups, and paired samples t-tests were used 
for within groups analysis of change. For comparison of categorical data between patient 
groups, the Chi square test for independence was used. Spearman’s correlation coefficients 
(rs) were used. One–way between-groups ANCOVA was performed, with preliminary checks 
to ensure no violation of the assumptions of normality, linearity, homogeneity of variances 
and homogeneity of regression slopes. Multiple linear regression analyses were performed, 
with log-transformation of parameters when needed, to ensure no violation of the assumptions 
of normality, linearity and homoscedasticity. In regression analyses Nordic = 1 and South 
Asians = 2. A two-sided p-value < 0.05 was deemed significant and uncorrected values are 
presented. In Paper III, Bonferroni-Holm corrections were also performed, and showed that 
uncorrected p-values < 0.01 remained < 0.05 after correction. Due to the exploratory nature of 
the studies, with somewhat limited sample sizes, uncorrected p-values were still kept in order 
to limit type II statistical errors (156). Statistical analyses were performed with SPSS 18.0 and 
19.0 for windows (SPSS Inc., Chicago, IL, USA).
3.2.13 Ethical aspects
All participants gave informed consent prior to any study related procedure. The studies were 
approved by the Eastern/South-Eastern Norway Regional Committee for Medical and Health 
Research Ethics, and conformed to the declaration of Helsinki of 1964 as revised in 2002 
(157) and GCP guidelines (158). The DIVINE study was registered with the US National 
Library of Medicine Clinical Trials registry, number NCT00992797. 
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4 Main results – summary of papers
4.1 Paper I
The aim of this paper was to explore possible differences in the pathophysiology of type 2 
diabetes in a group of younger Pakistani and Norwegian subjects with type 2 diabetes. The 
subjects were examined with a two-step euglycaemic, hyperinsulinaemic clamp, with 
measurements of NEFA every 30 minutes. Fasting blood samples and anthropometrical 
measurements were performed in all subjects, as well as body composition, assessed by BIA 
in a subgroup of 30 subjects. The Pakistani subjects had significantly lower BMI, but higher 
HbA1c and longer diabetes duration than the Norwegians did. We found no statistically 
significant crude differences in GIR or ISI during the first clamp step, although point 
estimates were consistently higher in the Norwegian group than the Pakistani group: median 
(inter-quartile range) GIR40YVȝPROPPLQ (p = 0.46), ISI40:
YVȝPROPPLQV-ins (p = 0.29). During the second clamp step GIR 
was still not significantly different, GIR400: 2055.6 (907.0) vs. 1661.1 (672.ȝPROPPLQ
(p=0.08), whereas ISI400 was significantly higher in Norwegians: 20.7 (17.2) vs. 14.2 (7.3) 
ȝPROPPLQV-ins (p=0.016). After adjusting for sex and percentage body fat, a borderline
significant lower insulin sensitivity in the Pakistani group was found, both measured as GIR40
(p=0.06), ISI40 (p=0.012), GIR400 (p=0.042) and ISI400 (p=0.014). We also found that the 
Norwegian subjects had higher percentage NEFA suppression after 30 minutes of clamp 
hyperinsulinaemia than Pakistani subjects: 71.2 (42.1)% vs. 41.9 (90.6)%, (p=0.042). BMI 
strongly correlated to insulin sensitivity in the Norwegian group, whereas the Pakistani group 
was quite insulin resistant regardless of BMI. Waist circumference correlated more strongly 
to insulin sensitivity in the Pakistani group than the Norwegian group, where the correlation 
was not significant. Leptin and IL-1RA were negatively associated with insulin sensitivity in 
the Norwegians but not the Pakistanis. Leptin and IL-1RA correlated negatively to BMI in 
both Norwegians and Pakistanis and with waist circumference in the Pakistanis only. These 
findings suggest that there may be important differences in the relationship between obesity, 
insulin sensitivity and the effect and/or regulation of these signal substances between the two 
groups. Leptin is known to correlate mainly to the amount of subcutaneous abdominal adipose 
tissue, and these findings could indicate ethnic differences in the metabolic activity of the 
different compartments of abdominal adipose tissue.
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4.2 Paper II
This paper further examined the relationship between insulin sensitivity, inflammation 
markers and abdominal fat distribution in the Norwegian and Pakistani groups described in 
paper I. Abdominal and thigh adipose tissue, liver fat and muscle compartments were 
examined with computed tomography scans. The study revealed similar areas of adipose 
tissue in the abdomen between the two groups, but differences in the relationship between 
adipose tissue compartments and insulin sensitivity as measured by the euglycaemic clamp. 
VAT correlated significantly negatively to insulin sensitivity in the Pakistani subjects only (rs
= -0.68, p = 0.006), Norwegians: (rs = -0.25, p = 0.304). Plasma levels of leptin were highly 
correlated to SAT in the abdominal and thigh area in both Norwegians and Pakistanis, with 
the strongest correlation in the Pakistani group. CRP was positively correlated to abdominal 
SAT in Pakistani patients only. IL-1RA on the other hand, correlated positively to abdominal 
and thigh SAT in Norwegian patients only. To conclude, in spite of similar adipose tissue 
distribution in the Norwegian and Pakistani patients, we found evidence of ethnic differences 
in the importance of adipose tissue distribution for insulin sensitivity and inflammation, 
where VAT seemed to be especially important in the metabolic dysregulation in Pakistani 
patients.
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4.3 Paper III
This paper describes more in depth analyses of glucose and fat metabolism in Nordic and 
South Asian subjects. Insulin sensitivity, insulin secretion and fat distribution as measured by 
euglycaemic clamp with isotope tracer dilution, indirect calorimetry, IVGTT and DXA were 
assessed. A group of 62 Nordic and South Asian subjects with type 2 diabetes included in a 
vitamin D intervention trial were examined at baseline. All participants had hypovitaminosis 
D. The South Asian group was significantly younger, shorter and leaner than the Nordic 
group, but had similar diabetes duration and higher HbA1c. The main finding was a 
significantly higher endogenous glucose production during the post-absorptive state in the 
South Asian group compared to the Nordic group: 19.1 (9.1) vs. 14.4 (6.8) μmol/kgFFM/min, 
p = 0.003. There were no differences between South Asians and Nordics in total glucose 
disposal (39.1 ± 20.4 vs. 39.2 ± 17.6, p = 0.99) or first phase insulin secretion (AUC0-8 min:
220 (302) vs. 124 (275), p = 0.35). Endogenous glucose production remained detectable in all 
subjects during clamp hyperinsulinaemia, and could not be reliably predicted by any 
parameters measured. There was no significant relationship between serum 25-
hydroxyvitamin D levels and insulin sensitivity or insulin secretion. There were near 
significant correlations between resting and clamp energy expenditure and endogenous 
glucose production in the South Asian group only, which could indicate increased post-
absorptive glucose metabolism at the expense of lipid metabolism in the South Asian group, 
but these results have to be confirmed in larger studies.
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5 Discussion
5.1 Methodological considerations
5.1.1 Patient characteristics
Differences in body composition 
The patients from the two ethnic groups that have been studied for this thesis display ethnic 
differences in the degree of adiposity and body composition. We experienced both in the 
DIPI-study and in the DIVINE- study that the Pakistani/South Asian groups were overall 
leaner and shorter than the Norwegian/Nordic groups, although we had different inclusion 
criteria and recruitment strategies in the two studies. This is at odds with the most common 
findings in literature, when comparing South Asian to Western subjects. The South Asian 
group tends to be more obese, at least concerning central obesity (113;159). There may be 
several explanations for this discrepancy. 
There is obviously a selection bias in the patients we recruited, since a large part has been 
recruited from the hospital outpatient clinics. In Norway type 2 diabetes is usually treated in 
general practice and only the more difficult cases are referred to specialist clinics. These 
patients may well be more obese than the regular person with type 2 diabetes, at least in the 
Norwegian/Nordic population. This may not necessarily be the case for the South Asians, 
though. We have seen that this ethnic group also in general practice often presents with poorly 
regulated diabetes (111). The South Asian patients referred to specialist clinics are therefore 
not necessarily very different from those treated in general practice. 
Another explanation for the discrepancies with other studies is the choice of inclusion criteria. 
We have chosen to examine established type 2 diabetic patients with median disease duration 
of 5 to 9 years in the various groups, whereas most of the studies published on insulin 
resistance in South Asians have in fact examined healthy or pre-diabetic subjects 
(113;128;160-162).
We have shown that the South Asian group is shorter and leaner, but find no difference in 
total percentage body fat, or in the areas of abdominal adipose tissue or ectopic fat infiltration. 
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The areas of muscle tissue in abdomen and thigh did tend to be lower in Pakistani patients, 
consistent with findings from other authors (114). The similar size of abdominal adipose 
tissue compartments in the two ethnicities might also be due to a selection of more obese 
Norwegian patients.
Differences in HbA1c
HbA1c has been consistently higher in the South Asian compared to the Nordic groups, both 
in the DIPI-study where the groups were similar in age, but where the Pakistani patients had 
longer disease duration, and in the DIVINE-study where the South Asians were significantly 
younger than the Nordic patients, but where disease duration was similar. This indicates that 
the South Asian patients have a disease that is more difficult to control, either owing to 
differences in quality of diabetes care, perhaps because of language barriers or cultural 
differences, or due to inherent differences in disease pathophysiology. Tran et al. have 
presented a study of quality of care for patients with diabetes in general practice in Oslo. In 
this study, different ethnic groups were found to have received comparable quality of diabetes 
care, but ethnic minority groups like the South Asians had earlier onset of diabetes and poor 
glycaemic control. This indicated a need for tighter follow-up and collaboration between 
general practice and specialist health care (111). This is in line with our findings, pointing 
towards higher insulin resistance, especially hepatic insulin resistance, with increased fasting 
endogenous glucose production, leading to more hyperglycaemia and higher HbA1c.
Differences in age
The patient groups studied in the DIPI-study and DIVINE-study differed in age through 
differences in inclusion criteria. This might be a reason for the different results seen in the 
measurements of insulin sensitivity. 
In the DIPI-study, the participants were selected according to age between 18 and 45 years. 
The two ethnic groups were similar in age, between 29 and 45 years old. Even in this young 
group of diabetes patients, the Pakistani group had significantly longer diabetes duration than 
the Norwegian group. In the DIVINE-study, there was no upper age limit at inclusion. The 
Nordic group ended up older than the South Asian group by approximately 10 years. 
However, the two groups in the DIVINE-study had similar diabetes duration. 
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5.1.2 Measurements of body composition
We have performed dual x-ray absorptiometry measurements and/or bioelectrical impedance 
analyses of body composition in both studies. It was known that DXA prediction models for 
fat mass and lean body mass established in a healthy white population could be less 
appropriate in other populations with a different body composition (163) however, this had 
not been properly investigated in South Asian men and women at the time we examined them. 
Taylor et al. have recently published a study validating DXA measurements of abdominal fat 
in Indians against MRI measurements (164). They found good overall agreement between 
DXA and MRI measurements, but there was evidence of an overestimation of fat mass by 
DXA at low values of abdominal fat, and in females. This strengthens the validity of our 
DXA measurements, with the reservation that Taylor et al. used a different DXA instrument 
than ours. For BIA there was growing evidence that ethnic specific algorithms should be used 
in BIA measurements. A few algorithms were published on South Asians/Asian Indians at the 
time of examination (68;165;166), however none using the Tanita analyser, and they proved 
difficult to use on our BIA registrations, with uncertainties regarding comparability with the 
BIA registrations in the Nordic participants. We therefore decided to use the standard 
algorithms embedded in the analyser software in measurements of all our participants. 
Waidyatilaka and co-workers has recently published a study validating a BIA equation in Sri 
Lankan urban women (66).
The discrepancies that might exist in the measurement of body composition by DXA, 
especially in the leanest women, might have moderately influenced the results in the South 
Asian group, where fat free mass might have been somewhat underestimated. Both fasting 
and clamp endogenous glucose production as well as total glucose disposal is expressed per 
kg fat free mass, measured by DXA. A systematic error in the estimation of fat free mass in 
lean South Asian women concerns only a few of the 61 subjects, and would therefore hardly 
have any influence on the data on insulin resistance and glucose metabolism. 
5.1.3 Hepatic glucose production
Many clamp studies are performed without measuring endogenous glucose production, 
although there is evidence that endogenous glucose production is not totally suppressed, at 
least in type 2 diabetic, insulin resistant subjects (56). In the DIPI-study, we did effectively 
experience difficulties in lowering blood glucose levels to euglycaemia during the first step of 
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the clamp in a number of patients, signifying that endogenous glucose production was not 
suppressed. We therefore used an approach with two steps of hyperinsulinaemia, to be able to 
measure insulin sensitivity in everybody. This method does however have some limitations. 
We found that it became impossible to complete the highest step of the clamp in some cases, 
where the subjects had near-normal insulin sensitivity, because the amount of glucose needed 
for the infusion to balance the hyperinsulinaemia exceeded recommended doses, and risked 
creating phlebitis. In addition, the highest step of the clamp induced serum insulin levels of 
10,000 pmol/l or more, which is very far from physiological insulin levels. Our experiences 
from the DIPI-study therefore lead us to conclude that we needed to measure endogenous 
glucose production in the DIVINE-study. The results from the DIVINE-study in fact showed 
a non-negligible endogenous glucose production during clamp, which was impossible to 
estimate through surrogate markers. This has further confirmed the need for measuring 
endogenous glucose production during euglycaemic clamps in subjects with insulin 
resistance, so as not to underestimate the total glucose disposal. 
5.1.4 Choice of equation for calculation of total glucose 
disposal
The most widely used method for calculating total glucose disposal by isotope tracer dilution 
is Steele’s equation for non-steady state glycaemia (167), here modified to account for 
addition of tracer to the variable glucose infusion (168):
ܴ௔ (ݐ) = ቈ
ܧ௕
ܧ௣(ݐ)െ 1቉ ܫ െ  
݌ܸܩ(ݐ) ൬݀ܧ௣ (ݐ)݀ݐ ൰
ܧ௣(ݐ) +  
ܧ௩௔௥ ×  ܫ௩௔௥
ܧ௣(ݐ)
We chose to opt for a simpler equation, which produced results that were comparable to 
results using Steele’s equation, but which did not produce negative values of total glucose 
disposal rates. These negative values are an artefact of Steele’s equation, which in fact is an 
equation for a single pool model used in a multiple pool system. It is a well-known 
phenomenon, and, of course, not physiologically possible. Our experience had been that even 
regular analytical variability in the deuterated glucose measurements during the periods of 
steady state euglycaemia created variations in dEp(t)/dt of Steele’s equation that became so 
important that this in several cases lead to negative values of EGP, although the actual 
variation in tracer concentration was negligible. This was seen both at the end of the basal and 
the clamp examinations. In addition, the use of a pool fraction, and the size of this pool 
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fraction is debated (169). As it turns out, when the dEp(t)/dt is low, then the pool fraction has 
little overall effect. We had minimized the variation in tracer to tracee ratio by adding tracer 
to the variable glucose infusion during the euglycaemic clamp (168). All measurements of 
total glucose disposal and endogenous glucose production were made in conditions of steady 
state, where the variation in plasma glucose was minimal. We therefore deemed it appropriate 
to use an equation for steady state: 
ܶܩܦ = ܫ × ܧ௜ + ܩܫܴ ×  ܧ௠ܧ௣(௖௟௔௠௣) െ ܫ
where I is the rate of [6,6-2H2]-glucose infusion (μmol/m2/min), Ei is the enrichment of the 
tracer infusion in moles percent excess (mpe), GIR is the exogenous glucose infusion rate 
(μmol/m2ǜmin), Em is the [6,6-2H2]-glucose enrichment (mpe) in the infused glucose, and 
Ep(clamp) is the mean [6,6-2H2]-glucose enrichment (mpe) in the plasma samples taken during 
the last 30 minutes of the clamp euglycaemia. 
5.1.5 Normalising the glucose infusion rates/total glucose 
disposal rates
The recommended way to obtain standardised indices of insulin sensitivity is to normalise the 
M-value (glucose infusion rate) for fat free mass, especially in obese subjects or in groups 
where both sexes are represented, to account for differences in body fat mass between 
subjects (170). In the DIPI-study, we unfortunately lacked data on fat free mass in 
approximately ¼ of the patients. The glucose infusion rate was therefore normalised for body 
surface area. We also showed results both non-normalised and normalised for serum insulin 
values at each euglycaemic clamp step, to account for differences in insulin clearance and the 
ability of exogenous insulin to suppress endogenous insulin secretion. According to De 
Fronzo et al (171), this insulin sensitivity index, a measure of the amount of glucose 
metabolised per unit of insulin concentration, should be an appropriate way to express insulin 
sensitivity. However, the importance of normalising for serum insulin levels is disputed, since 
it has been demonstrated that the high variability in mean GIR values observed in various 
studies of normal-weight, non-elderly, non-diabetic subjects becomes even greater when 
normalised to serum insulin (172). Also, the clearance rate of insulin becomes non-linear 
above a certain level of serum insulin (approximately 3500 pmol/l), and in these supra-
physiological circumstances it is difficult to know the level of insulin action on peripheral 
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tissues (172). In the DIVINE-study, we therefore chose to normalise the total glucose disposal 
for fat free mass only, and not for serum insulin levels. 
5.1.6 Differences in obesity and the relation to adipokines and 
inflammation
A limitation to our studies was that the Norwegian/Nordic groups were significantly more 
obese than the Pakistanis/South Asians. In the DIPI-study, this could have attenuated possible 
differences in adipokines and markers of inflammation, such that they became impossible to 
discern, given the limited group sizes as well. There was no difference in leptin levels. 
However, with the higher total body fat mass in Norwegians, one would have expected higher 
leptin levels in this group, since leptin is mostly produced in subcutaneous adipose tissue (22),
the largest of the adipose tissue compartments. This could signify that matching the groups 
for degree of obesity could have shown higher leptin levels in the Pakistani group. Adjusting 
for parameters of obesity did, however, not unmask such a difference in our material. The 
point estimates of sTNF-R1 and adiponectin, are lower in the Pakistani group than in the 
Norwegian group, although the difference does not reach statistical significance (p=0.14 and 
0.15 respectively). Adiponectin shows no association with adipose tissue compartments or 
total body fat.  There was only an indirect association with insulin sensitivity, (data not shown
in paper I); when dividing patients into two groups according to adiponectin levels higher or 
lower than median, we found significantly higher ISI400 levels in the high adiponectin group 
compared to the low adiponectin group in the Norwegian patients, (24.1 (11.2) vs. 13.2 
(12.6), p=0.048), but not in the Pakistani patients, (15.6 (19.8) vs. 12.8 (6.1), p=0.841). 
5.1.7 Sample size and power
In the DIPI-study, we calculated sample size and power from available results in earlier 
studies, which were performed in other diabetes patient populations, mainly older. These 
results, in fact, underestimated the variance in the clamp measurements of insulin sensitivity. 
The variance, especially in our Norwegian group of young type 2 diabetic individuals, was 
much higher than anticipated. The DIPI-study therefore turned out somewhat underpowered.
The DIVINE-study was an intervention trial, where power calculations were performed for 
the main outcome, which was change in insulin sensitivity from baseline to end of trial in the 
treatment group compared to the placebo group. Recruitment was focused on the intervention 
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study, and no matching of the two ethnic groups concerning age, HbA1c or body composition 
was made. We had intended to include 30 patients from each ethnic group, but the recruitment 
of South Asian patients proved more difficult than anticipated, leading us to reduce the South 
Asian group and increase the Nordic group. It was also more difficult to get the South Asian 
subjects to undergo a complete set of examinations. Some patients declined the indirect 
calorimetry measurements due to claustrophobia from the canopy hood. The South Asian 
group was therefore more limited than first intended was.
5.2 Main findings
5.2.1 Insulin sensitivity
The results from the DIPI study, which showed reduced insulin sensitivity in the Pakistani 
group, are in line with findings in other studies in South Asian subjects with type 2 diabetes 
(125;173). The DIPI study was performed without measurement of endogenous glucose 
production, and therefore did not measure true total glucose disposal, only the exogenous 
glucose infusion rate. In the DIVINE-study, we performed more thorough examinations of 
total glucose disposal and glucose metabolism, including measurements of endogenous 
glucose production, something that has not been published previously in South Asians with 
type 2 diabetes. We found significantly higher post-absorptive endogenous glucose 
production in the South Asian group. Endogenous glucose production during clamp 
hyperinsulinaemia was, however, not significantly different in the two groups, although 
endogenous glucose production given as a percentage of total glucose disposal tended to be 
higher in South Asians. After adjustment for central adiposity, in the form of waist-to-height 
ratio, this percentage became significantly higher in the South Asians, signifying higher 
hepatic insulin resistance. 
Contrary to our expectations, we found no ethnic difference in total glucose disposal in the 
DIVINE-study. The South Asian group, in particular, is of limited size in the DIVINE study.
It is possible that we could have found a difference in total glucose disposal given a larger 
study sample, and if the two ethnic groups had been matched for body composition. Adjusting 
for waist circumference, amongst other factors, did increase the difference in TGD between 
the groups, although no significant difference was unveiled. 
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It is also possible that the main ethnic difference in insulin resistance in fact lies primarily in 
the higher hepatic insulin resistance in South Asians. Hepatic insulin resistance impairs 
insulin’s ability to suppress endogenous glucose production. The need for exogenous glucose 
infusion during clamping would naturally be much lower in South Asians, where a relatively 
higher rate of endogenous glucose production persisted. In view of the fact that the peripheral 
glucose uptake did remain similar in the two ethnic groups, this implies that the level of 
peripheral insulin sensitivity is the same in the two ethnic groups. If this is the case, a larger 
focus on the hepatic glucose and lipid metabolism in the South Asian population is warranted, 
to elucidate possible causes, and thereby develop better treatment strategies.
Increased hepatic insulin resistance can be caused by excess NEFA, which inhibit the insulin 
receptor signalling pathways, and prevent the insulin mediated inhibition of gluconeogenesis 
and glycogenolysis (5). We have seen in the DIPI study that NEFA suppression during 
euglycaemic clamp hyperinsulinaemia was significantly impaired in the Pakistani group. 
The adipose tissue overflow hypothesis constitutes one intriguing explanation for excess 
NEFA in the liver (139). The “overflow” of lipids to the more metabolically active 
compartments, i.e. deep subcutaneous and visceral adipose tissue increases their metabolic 
activity even more, thus releasing more NEFA into the circulation, with transportation to the 
liver. In the DIPI study we have seen that DSAT and VAT correlated significantly to insulin 
sensitivity in Pakistani, but not in Norwegian subjects, in accordance with this hypothesis. 
The NEFA flux to the liver and peripheral tissues also increases ectopic fat depositions. We 
have not seen increased fatty infiltration in the liver in South Asian groups. However, in the 
DIPI-study we also showed a significant correlation between the insulin sensitivity index and 
liver attenuation in the total patient group. The correlation coefficient in the Pakistani group 
was of similar magnitude as in the total group, but did not reach significance, probably due to 
the smaller group size.
With possibly increased levels of NEFA in the liver, and perhaps also in skeletal muscle, the 
metabolic inflexibility hypothesis can come into light (141). As previously stated, NEFA 
suppression during hyperinsulinaemic clamp was significantly impaired in Pakistani subjects 
in the DIPI-study. A sign of metabolic inflexibility is blunting of the usually rapid decline in 
plasma NEFA following the first phase insulin secretion at the beginning of a meal (174). If 
we transfer this to the euglycaemic clamp setting, this is in line with our findings in the DIPI-
study. We do have data from meal tests in this cohort, which will be interesting to look into 
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further. With regard to the muscular fuel switch, we have not performed any measurements of 
pure skeletal muscle metabolism, such as limb balance methods (141), so the evidence of 
metabolic inflexibility in muscle will have to be circumstantial. 
5.2.2 Glucose metabolism
In the DIVINE-study, we were able to study glucose metabolism in more detail, both looking 
at endogenous glucose production and further metabolism through oxidative and non-
oxidative glucose disposal. We were limited by the low number of South Asians who 
underwent indirect calorimetry measurements. However, we did find indications, although not 
statistically significant, that the higher endogenous glucose production in the South Asian 
group resulted in higher both oxidative and non-oxidative glucose metabolism in the post-
absorptive state. In the post-absorptive state, the organism mainly uses lipids as energy 
substrate. However, with increased plasma glucose levels, glucose will compete with NEFA 
as substrate for energy production, hence the oxidative glucose metabolism will increase. 
There is also some excess glucose and NEFA which has been metabolised in muscle into 
trioses/lactate/pyruvate. Instead of entering the citric acid cycle, they are returned to the liver 
through the Cori cycle or the glucose-alanine cycle to become substrates for gluconeogenesis. 
This implies that the post-absorptive hyperglycaemia participates in its own self-maintenance 
by the non-oxidative recycling, and is reinforced by hyperlipidaemia, where non-oxidative 
degradation of NEFA also becomes a substrate for gluconeogenesis in the liver. Our findings 
are thus in line with the theory of adipose tissue overflow, and of metabolic inflexibility, with 
increased use of glucose as energy substrate in the fasting condition, due to hyperglycaemia. 
Is there evidence in our studies for increased mitochondrial efficiency in the South Asian 
subjects? We have in fact measured lower resting energy expenditure in South Asians, 
although this was mainly due to lower FFM. We have so far not analysed any polymorphisms 
of the UCP 2 or 3 genes. Our groups are probably too limited in size to find ethnic 
differences.
5.2.3 Body composition
One of the hypotheses for the difference in prevalence of type 2 diabetes between the Western 
European and South Asian population in Western countries has been a difference in body 
composition, leading to a higher degree of insulin resistance. Several studies have shown that 
60
South Asians were more abdominally obese, with higher waist circumferences or larger 
abdominal adipose tissue compartments, correlating to measures of insulin sensitivity 
(113;114;159;175;176). However, most of these studies have been performed in non-diabetic 
subjects, and used surrogate markers for insulin resistance, like the HOMA IR. In our two 
studies, most of our subjects were obese, both in the South Asian and in the Nordic groups, 
although the Nordic subjects were significantly more obese than the South Asians, both 
regarding waist circumference and BMI. Interestingly, when comparing abdominal adipose 
tissue compartments in the two ethnic groups in the DIPI-study, there were no significant 
differences, neither in area of subcutaneous nor visceral adipose tissue. The degree of fatty 
infiltration in the liver was also similar. Still, the Pakistani subjects in the DIPI-study had 
lower insulin sensitivity than the Norwegian subjects, and VAT was strongly negatively 
correlated to insulin sensitivity in the Pakistani group only. One way to interpret this finding 
is that it is not the amount of adipose tissue per se that is important for insulin resistance and 
diabetes risk. There must be one or even several other factors making the central obesity in 
South Asians more deleterious than in Western Europeans. The fact that visceral adipose 
tissue was correlated to insulin sensitivity in the Pakistani and not in the Norwegian group 
supports this. We therefore investigated the role of several adipokines and inflammation 
markers, to see if they could represent this factor, discussed in a later section. 
Another possible explanation for the higher insulin sensitivity in the Norwegian group, 
despite higher levels of obesity and similar areas of abdominal adipose tissue compartments, 
is that in the DIPI-study, we recruited young subjects who had been diagnosed with diabetes 
in early adulthood, which is more uncommon in the Norwegian than in the Pakistani 
population. It is possible that these selected young Norwegians have a different kind of 
diabetes, where obesity and other traditional risk factors are less important, and where a 
genetic or other inherited susceptibility is the most important factor. We did however also 
observe a highly significant correlation between insulin sensitivity and BMI in the Norwegian 
group only. From GWAS studies it is recognized that few susceptibility genes for type 2 
diabetes that until now has been identified, are involved in obesity and insulin resistance 
(FTO, PPARG), whereas the large majority involve insulin secretion and ȕ-cell function (48).
In the Norwegian group, the range of insulin sensitivity was much larger, with several 
subjects having near normal values, but still they had developed type 2 diabetes. We cannot 
exclude that some of these subjects do not have typical type 2 diabetes, and may have 
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monogenic diabetes. They were, however, older at time of diagnosis than the typical patient 
with monogenic diabetes was. (177).
5.2.4 Inflammation
We wanted to investigate whether the difference in diabetes prevalence could be caused by a 
higher degree of low-grade inflammation in the South Asians, contributing to higher insulin 
resistance. Several other studies have reported lower levels of adiponectin, higher levels of 
leptin, CRP and other inflammation markers in South Asians with or without diabetes 
(113;178-180). In the DIPI-study, several adipokines/inflammation markers were measured, 
but we found no ethnic differences in plasma levels of these substances. There were however, 
differences in the relationship between these adipokines and insulin resistance and body 
composition, where leptin and IL-1RA correlated negatively with insulin sensitivity in the 
Norwegian group only. These adipokines are mainly linked to subcutaneous adipose tissue, 
indicating that SAT might have a more important role in insulin sensitivity in the Norwegian 
group than in the Pakistani group, perhaps due to the higher degree of obesity. Adiponectin 
also seemed to play a more important role for insulin sensitivity in Norwegians than in 
Pakistanis, contrary to previous reports. Leptin correlated significantly positively with SAT in 
both abdomen and thigh in Norwegian and Pakistani patients, while IL-1RA only correlated 
with SAT in Norwegians. CRP on the other hand, significantly correlated to SAT only in the 
Pakistani group. Surprisingly, none of the adipokines/inflammation markers correlated with 
VAT, and there was no significant correlation between adipose tissue compartments and IL-6.
This seems to indicate that the importance of VAT for insulin resistance in Pakistanis is not 
mediated by the markers we have measured. There might of course be other inflammation 
markers involved, that we have not measured. One could also speculate that NEFA could be 
an important factor, although fasting NEFA values did not differ between the two groups. 
These were however analysed in peripheral plasma, and not in the portal circulation. 
5.2.5 ȕ-cell function
In the DIVINE-study, we assessed the first phase insulin secretion through intravenous 
glucose tolerance tests. We did not find any significant ethnic difference in the acute insulin 
response to glucose (AIRg). However, the groups were of limited size, and first phase insulin 
secretion only gives us part of the picture regarding ȕ-cell function. Contrary to the 
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euglycaemic hyperinsulinaemic clamp for insulin resistance, there is no gold-standard method 
to investigate insulin secretion and ȕ-cell function (181). The subjects all had established type
2 diabetes, where AIRg is often said to be lost (182). Still, we found some increase in insulin 
AUC in 53 out of 60 subjects, and two thirds had AIRg above 100 pmol x min/l.
As previously mentioned, insulin resistance could also affect the ȕ-cell, leading to ȕ-cell 
dysfunction through inhibition of glucose mediated insulin secretion (6). In the DIPI-study, 
the Pakistani subjects had a non-significant tendency towards lower fasting serum C-peptide 
than the Norwegians, and in the DIVINE-study, the South Asians had significantly lower 
fasting C-peptide than the Nordic subjects, despite a tendency towards higher fasting plasma 
glucose. This lower fasting insulin production could also be a contributing factor for the 
higher basal, post-absorptive endogenous glucose production. The raised fasting endogenous 
glucose production, and increased hyperglycaemia could in part be explained by ȕ-cell 
dysfunction resulting in inadequate insulin secretion. However, adjusting the EGP for fasting 
C-peptide did not eliminate the ethnic difference in EGP. 
More pronounced impaired ȕ-cell function has been reported in South Asians with gestational 
diabetes (GDM). Kousta et al. showed lower HOMA-B and lower AIRg than controls in 
South Asian post-GDM women (183). Mørkrid et al. showed that South Asian women with 
GDM increased in insulin resistance from gestational week 15 to week 28, similar to 
Norwegian women, but their ȕ-cell function (HOMA-B) increased significantly less, and 
hence did not match the change in insulin resistance (184).
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6 Conclusions and clinical 
implications
6.1 Conclusions
The main conclusions of this thesis are: 
x South Asian subjects with type 2 diabetes have a higher degree of hepatic insulin 
resistance.
x Whether an ethnic difference in peripheral insulin resistance also exists, has not been 
completely elucidated by these studies. 
x The Nordic subjects in both studies were more obese than the South Asians. Despite 
this, there were no significant differences in the size of adipose tissue compartments. 
The muscle compartments in abdomen and thigh were however smaller in the 
Pakistani women, and abdominal muscle compartment also bordered on smaller in 
Pakistani men. 
x The visceral adipose tissue, although not larger, was more metabolically active, with a 
strong correlation to insulin resistance in South Asians.
x There were no differences in blood levels of adipokines/markers of inflammation 
measured. The relationship between adipokines and adipose tissue compartments 
could not explain the ethnic difference in insulin resistance.
x There was no ethnic difference in ȕ-cell function measured by first phase insulin 
secretion during IVGTT. However, fasting C-peptide was lower in South Asians 
despite higher fasting plasma glucose, indicating a possibility of impaired basal insulin 
secretion.
x South Asians had significantly higher basal endogenous glucose production. 
x South Asians had lower resting energy expenditure than Nordics, mainly due to lower 
amount of fat-free body mass.
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6.2 Clinical implications
We have shown that South Asian subjects have higher endogenous glucose production, 
signifying hepatic insulin resistance. Whether peripheral insulin resistance also is higher is 
still uncertain. This should be kept in mind when treating this patient group. The general 
advice of lifestyle modifications and metformin as the basis of treatment in type 2 diabetes 
should indeed also apply to these patients, and they should possibly be kept on metformin 
treatment for as long as possible, to counteract some of the hepatic insulin resistance. 
We have moreover shown that visceral adipose tissue is correlated to insulin resistance in the 
South Asian group. It would therefore be natural to target weight loss as an important means 
of improving insulin sensitivity, although we have not shown directly in our studies that 
weight loss improves insulin sensitivity in this group.
Both the DIPI and the DIVINE-study showed higher HbA1c in the Pakistani/South Asian 
groups; in line with Tran’s findings in her study of quality of diabetes care in general practice
(111). This underlines the importance of treating this group of patients aggressively, to 
achieve acceptable goals of glucose control.
6.3 Further research
There is a need for further studies of insulin, glucose and lipid metabolism in South Asians, to 
verify the results of this thesis, and further explore the aetiology of insulin resistance in this 
ethnic group. 
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Differences in insulin sensitivity, lipid metabolism
and inflammation between young adult Pakistani
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Abstract
Background: Immigrants from South Asia to Western countries have a high prevalence of type 2 diabetes mellitus
(T2DM). We explored pathogenic factors that might contribute to the high risk of T2DM in Pakistani immigrants to
Norway.
Methods: A cross-sectional study was performed in 18 Pakistani and 21 Norwegian men and women with T2DM
(age 29 – 45 years), recruited from two hospital out-patient clinics. Anthropometrics and a two-step euglycemic,
hyperinsulinemic clamp with measurements of non-esterified fatty acids (NEFA) during clamp, was performed in all
patients. Insulin sensitivity, given as the Glucose Infusion Rate (GIR) and Insulin Sensitivity Index (ISI), was calculated
from the two euglycemic clamp steps. Fasting adipokines and inflammatory mediators were measured. Continuous
variables between groups were compared using Student’s t test or Mann–Whitney U test as appropriate.
Spearman’s correlation coefficient and multiple linear regression analyses were used.
Results: Despite having a lower BMI, Pakistani patients were more insulin resistant than Norwegian patients, during
both low and high insulin infusion rates, after adjustment for sex and % body fat: median (interquartile range) GIR
(low insulin): 339.8(468.0) vs 468.4(587.3) μmol/m2/min (p = 0.060), ISI(low insulin): 57.1(74.1) vs 79.7(137.9) μmol/m2/min
(p = 0.012), GIR(high insulin): 1661.1(672.3) vs 2055.6(907.0) μmol/m2/min (p = 0.042), ISI(high insulin): 14.2(7.3) vs 20.7(17.2)
μmol/m2/min (p = 0.014). Pakistani patients had lower percentage NEFA suppression 30 minutes into clamp
hyperinsulinemia than Norwegians: 41.9(90.6)% vs 71.2(42.1)%, (p = 0.042). The relationship of ISI to BMI, leptin and
interleukin-1 receptor antagonist also differed between Norwegians and Pakistanis.
Conclusions: Compared with Norwegian patients, Pakistani patients with T2DM had lower insulin sensitivity,
affecting both glucose and lipid metabolism. The relation of insulin sensitivity to BMI and some adipokines also
differed between the groups.
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Background
Immigrants from South Asia to Western countries have
a high prevalence of Type 2 diabetes mellitus (T2DM)
[1-4]. The prevalence is also high in urban areas in their
countries of origin [5-7]. Studies comparing non-diabetic
subjects from India and the US indicate that Indians
have lower insulin sensitivity [8,9]. Norway, like many
other Western countries, has a growing population of
immigrants, with one of the largest groups being of
Pakistani origin. This group has an alarming prevalence
of T2DM, manifesting at a younger age than in ethnic
Norwegians [10], and reaching more than 25% in 30–
60 year old South Asian women living in an Eastern sub-
urb of Oslo [11]. Better knowledge through studies of
the pathophysiology of T2DM in this population is
necessary to develop more efficient prevention and treat-
ment strategies. Such studies could also give new insight
into the pathogenesis of T2DM in general.
There is a well known association between obesity and
T2DM, but South Asians develop T2DM at lower levels
of body mass index (BMI) than Westerners, and are
more insulin resistant for any given BMI [12,13]. Several
studies have indicated that, in individuals from South
Asia, BMI may be inferior to other measures of adiposity
as a predictor of metabolic risk [13-15].
Adipokines and inflammatory mediators derived from
adipose tissue may be important in the pathogenesis of
insulin resistance and T2DM [16]. Possible differences
in the profile of these substances between South Asians
and Westerners with T2DM, could potentially help
explain differences in the development of T2DM in
these groups.
In the present study, we investigated a group of young
adult immigrants from Pakistan with T2DM, and com-
pared them to a group of Norwegian patients of similar
age. We chose to study young adult subjects, where dis-
ease duration was relatively short, to avoid comorbidities
that might confound the interpretation of our data. Our
aim was to explore differences between the groups with
regards to pathogenic factors such as insulin resistance,
obesity and inflammation, which might contribute to the
high prevalence of T2DM in Pakistani immigrants to
Norway.
Methods
Design
This was a cross-sectional study comparing young T2DM
patients from two different ethnic groups.
Patients
Norwegian and Pakistani patients withT2DM, aged 45 years
or younger, attending the out-patient clinics at Lovisenberg
Deaconess Hospital between 1999 and 2005, and Aker
University Hospital between 2003 and 2009,were eligible
for inclusion. After searches in the two hospitals’ patient
registries, 195 patients were randomly selected to receive
an invitation to participate in the study. Exclusion criteria
were: ethnicities other than Norwegian or Pakistani, posi-
tive GAD or IA2 auto-antibodies, age > 45 years, person
unwilling or unable to give informed consent. Patients were
contacted by letter with information about the study in
Norwegian and Urdu, and patients whose telephone num-
ber could be obtained were also informed by phone. Nine-
teen Pakistani and 21 Norwegian sex-matched patients (age
29–45 years, 49% men) with confirmed T2DM, agreed to
participate, and were included in the study. Participant
characteristics were similar to a subgroup of approximately
80 of the 155 patients not included, where data on HbA1c
and anthropometrics were available. All Pakistani partici-
pants were first generation immigrants. One Pakistani
woman was excluded on the first day of testing, because of
difficulties in obtaining intravenous access. The remaining
39 patients were examined.
Anthropometrical measurements
Height and weight were measured with participants
wearing light clothing and without any shoes on. Waist
and hip circumferences were assessed with a tape meas-
ure at mid point between the lowest rib margin and the
iliac crest, and at the level of the major trochanter,
respectively. Bioelectrical impedance analysis (BIA) was
performed on a Tanita Body Composition Analyzer BC-
418 (Tokyo, Japan). All subjects were fasting and voided
urine before measurement.
Euglycemic clamp
To enhance comparability of examinations, all patients
stopped taking oral antidiabetic drugs for two days, and
insulin for at least 12 hours prior to examination. Pa-
tients were asked to refrain from strenuous physical
exercise and alcohol intake during these two days, and
to fast from midnight during the night before the exam-
ination. We performed a euglycemic, hyperinsulinemic
clamp, using a modification of the method originally
described by De Fronzo et al. [17]. The clamp was
performed with two steps, first administering a primed,
continuous insulin dose of 40 mU/m2/min for a mini-
mum of 100 minutes, until at least 30 minutes of stable
euglycemia was obtained. This was directly followed by a
400 mU/m2/min insulin infusion, also for a minimum
of 100 minutes, with at least 30 minutes of stable
euglycemia at the end. The body surface area was calcu-
lated using Mostellers equation [18].
Human insulin (Actrapid®, Novo Nordisk, Bagsvaerd,
Denmark) 300 mU/mL and Glucose 200 mg/mL were
infused through a teflon catheter in a vein at the left
elbow of the patient. Insulin was diluted in NaCl 0.9%,
after having first added 2 ml of the patients own blood,
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to avoid insulin sticking to the walls of the bag. All
blood samples were drawn from a teflon catheter in a
vein at the right elbow, kept open by a slow infusion of
NaCl 0.9%. The right arm was kept at 37°C by a heating
sleeve connected to a thermal control unit (Swetron AB,
Veddestad, Sweden), to arterialize blood samples. Plasma
glucose was measured every five minutes using a
OneTouch Ultra glucose measuring device (LifeScan,
Milpitas, CA), with control measurements every 30
minutes by the glucose oxidase method, on a Glucose
Analyzer II (Beckman Instruments, Fullerton, CA). At
the end of each step of the clamp, three measurements
of serum insulin were taken at ten-minute intervals. The
glucose infusion rate in μmol/m2/min was established,
and denoted GIR40 and GIR400 respectively. Because of
varying metabolic clearance rates of insulin, the insulin
levels measured at the end of each step of the clamp
differed between patients. The insulin sensitivity index
(ISI) was therefore also calculated, and expressed as the
ratio of the GIR to the prevailing mean serum insulin
levels ((GIR/I) × 100), denoted ISI40 and ISI400. Every
30 minutes during the 2 step euglycemic clamp, EDTA
plasma for non-esterified fatty acid (NEFA) measure-
ments was extracted and immediately frozen at −70°C.
Two Norwegian and two Pakistani patients did not at-
tain euglycemia during the first step of the clamp, and
were excluded from this part of the clamp analyses. Two
Norwegian and four Pakistani patients were not examined
with the high-step clamp, due to contraindication of hy-
perosmolar glucose at high infusion rates (for the most
insulin sensitive patients) and long duration of the low-
step part of the clamp to reach euglycemia (for the most
insulin resistant patients). After excluding these patients
from clamp analyses, there were 46% men in the first step
and 48% men in the second step of the clamp.
Blood samples
Fasting plasma glucose was measured by the glucose
oxidase method on a Glucose Analyzer II (Beckman Instru-
ments). Serum insulin was analyzed using the radio-
immunoassay (RIA) kit, formerly from Linco Research Inc.
(St. Charles, MO), presently available from Millipore Corp.
(Billerica, MA). Plasma HbA1c was measured by high
performance liquid chromatography on a Variant analyzer
(Bio-Rad, Richmond, CA). Fasting serum total cholesterol,
serum HDL cholesterol, and serum triglycerides were
measured using a routine enzymatic method (Roche Diag-
nostics, Mannheim, Germany). Serum LDL cholesterol
was calculated using the Friedewald equation [19]. NEFA
were analyzed using a NEFA C enzymatic color test kit,
(Wako Chaemicals GmbH, Neuss, Germany), modified to
run on a Technicon RA1000 (Technicon Instruments
Corp., Tarrytown, NY). Plasma levels of adiponectin and
leptin were analyzed using RIA kits from Millipore Corp.
(Billerica, MA),(also formerly from Linco Research Inc.
(St. Charles, MO)). Plasma measurements of soluble
tumor necrosis factor-receptor type 1 (sTNF-R1) and high
sensitive C-reactive protein (hsCRP) were performed using
DuoSet ELISA kits from R&D Systems (Minneapolis, MN).
Plasma measurements of interleukin-1 receptor antagonist
(IL-1RA) were performed using CytoSet from Invitrogen
Corporation (Carlsbad, CA), with streptavidin-horseradish
peroxydase from R&D Systems. Plasma measurements of
interleukin-6 (IL-6) were performed using a High Sensi-
tivity ELISA kit from Abcam plc. (Cambridge, UK).
Statistical analysis
Data are presented as mean ± SD, or median (interquartile
range) as appropriate. We analysed non-normally dis-
tributed data log-transformed, or with the use of non-
parametric methods. Student’s t test or Mann Whitney U
tests were used for comparison of continuous variables
between groups. For correlations, Spearman’s correlation
coefficient (rs) was used. Multiple linear regression analyses
were performed with log-transformation of parameters
when needed, to obtain normally distributed residuals. A
two-sided p-value <0.05 was considered significant, but
owing to the large number of comparisons, particular atten-
tion should be directed towards analyses where p-values
are <0.01. Statistical analyses were performed with SPSS
18.0 for Windows (SPSS Inc., Chicago, IL).
Ethics
The study was carried out in accordance with the
Helsinki Declaration, and approved by the Eastern
Norway Regional Committee for Medical and Health
Research Ethics. Informed, written consent was obtained
from each participant before enrolment.
Results
Ethnic differences in diabetes duration and
anthropometrics
The two ethnic groups did not differ significantly in age,
sex and fasting plasma glucose. In contrast, BMI and
weight, including both total body fat mass and lean body
mass were significantly higher in the Norwegian, com-
pared with the Pakistani group (Table 1). Despite lower
BMI, Pakistani patients had higher median HbA1c, longer
median duration of diabetes, and a tendency towards earl-
ier onset of diabetes (reported mean age at onset 30 years
vs 34 years, p = 0.06). Further clinical characteristics of the
participating patients are presented in Additional file 1.
Ethnic differences in insulin sensitivity
When examining insulin sensitivity with a two-step
euglycemic, hyperinsulinemic clamp, median values for
GIR and ISI showed consistently higher point estimates
in the Norwegian compared to the Pakistani group,
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although we found no statistically significant crude differ-
ences between the groups in GIR or ISI during the first
step (Table 2). However, when adjusting for sex and %
TBF in a multiple regression analysis, LogGIR40 showed a
clear tendency towards lower values in the Pakistani
group, and LogISI40 was significantly lower in the
Pakistani compared to the Norwegian group (Table 3).
Further adjustment for BMI, HbA1c or diabetes duration
did not change the relation of ISI40 or GIR40 to ethnicity.
Ethnicity, sex and % TBF together explained 55% of the
variation in insulin sensitivity, expressed as ISI40. During
the second step of the clamp, Pakistani patients had non-
significantly lower median GIR400, and significantly lower
ISI400 (Table 2). In standard multiple regression analyses,
ethnicity and % TBF explained 29% of ISI400 and 24% of
GIR400 variation (Table 3). Sex was no longer a significant
predictor of LogISI400 or Log GIR400, and neither was
BMI, diabetes duration or HbA1c.
Ethnic differences in the relation of BMI and waist
circumference to insulin sensitivity
When exploring the relationships between anthropomet-
ric characteristics and insulin sensitivity, we found a
strong, significant correlation between ISI40 and BMI in
the Norwegian group, and a weaker, non significant cor-
relation in the Pakistani group. Waist circumference,
however was significantly correlated with ISI40 in the
Pakistani, but not in the Norwegian group (Figure 1a-b
and Additional file 2). There was also a significant in-
teraction between ethnicity and LogBMI (p = 0.032) in a
multiple regression analysis, suggesting a difference be-
tween the ethnic groups. (Dependent variable: LogISI40,
independent variables: ethnicity (p = 0,026), LogBMI (p =
0,004), as well as ethnicity x LogBMI). We were, however,
not able to confirm an ethnic difference in the relationship
between insulin sensitivity and waist circumference by
regression analysis (data not shown).
Ethnic differences in suppression of non-esterified
fatty acids
There were no significant differences in fasting NEFA
values between Norwegian and Pakistani patients, but
initial NEFA suppression by hyperinsulinemia, expressed
as percentage suppression of NEFA after 30 minutes
of the clamp, was significantly more pronounced in
the Norwegian group compared to the Pakistani group
(Figure 2, Table 2).
Adipokines and markers of inflammation
Table 4 shows levels of adipokines and markers of
inflammation in the two ethnic groups. The Norwegian,
but not the Pakistani group, showed negative cor-
relations between ISI40 and leptin, as well as IL-1RA
(Additional file 2). Fasting IL-1RA was significantly posi-
tively correlated to BMI in both patient groups. In the
Norwegian group it was also positively correlated to
Table 1 Clinical characteristics of patients according to
ethnic group
Norwegians Pakistanis
n = 21 n = 18 p
Males (%) 10 (48%) 9 (50%)
Age (years) 42 (6) 41 (8) 0.865
Years with diabetes 5 (9) 9 (7) 0.021
Weight (kg) 106.8 ± 13.6 90.1 ±23.4 0.009
BMI (kg/m2) 37.2 (6.0) 30.9 (9.4) 0.008
Waist circumference (cm) 114.3 ± 10.9 106.5 ±17.4 0.102
Waist-hip ratio 1.00 ± 0.09 1.01 ± 0.09 0.575
Total body fat (%) 36.9 ± 9.6 34.2 ± 7.7 0.395
Total body fat mass (kg) 39.5 ± 12.0 28.0 ± 8.2 0.005
Lean body mass (kg) 67.1 ± 12.6 54.2 ± 12.2 0.007
Fasting plasma glucose
(mmol/l)
10.7 ± 3.2 10.6 ± 3.3 0.973
HbA1c (%/mmol/mol) 7.3/56 (1.4/13) 8.7/72 (2.9/31) 0.022
Fasting insulin (pmol/l) 166 (160) 209 (193) 0.405
Fasting C-peptide (pmol/l) 1162 ± 458 977 ± 373 0.193
Total cholesterol (mmol/l) 4.5 ± 1.0 4.7 ± 1.3 0.512
HDL cholesterol (mmol/l) 1.03 ± 0.21 1.08 ± 0.24 0.557
LDL cholesterol (mmol/l) 2.7 ± 0.8 2.6 ± 0.6 0.868
Triglycerides (mmol/l) 1.6 (1.1) 1.4 (1.1) 0.832
Table 1: For normally distributed parameters, mean ± SD is given, and
comparisons were made using Student’s t test. For non-normally distributed
parameters, median (interquartile range) is given, and comparisons were made
using the Mann–Whitney U test. Median HbA1c-values are reported as NGSP-
%/IFCC-mmol/mol with interquartile range in parentheses. In bold: p < 0.05.
Table 2 Insulin sensitivity and NEFA suppression
Norwegians Pakistanis p
GIR40 468.4 (587.3) 339.8 (468.0) 0.456
ISI40 79.7 (137.9) 57.1 (74.1) 0.289
S-insulin end low step
(pmol/l)
546 (336) 715 (243) 0.041
GIR400 2055.6 (907.0) 1661.1 (672.3) 0.080
ISI400 20.7 (17.2) 14.2 (7.3) 0.016
S-insulin end high step
(pmol/l)
9505 (2738) 11082 (2922) 0.069
Fasting p-NEFA
(mmol/l)
0.59 (0.43) 0.50 (0.29) 0.394
NEFA suppression
0–30 minutes (%)
71.2 (42.1) 41.9 (90.6) 0.042
Table 2: Data are presented as median (interquartile range), and comparisons
are made using the Mann–Whitney U test. In bold: p < 0.05. GIR40 = glucose
infusion ratelow step, ISI40 = glucose infusion rate/s-insulinlow step, GIR400 =
glucose infusion ratehigh step, ISI400 = glucose infusion rate/s-insulinhigh step. GIR
is expressed as μmol/m2/min, and ISI as 100 × μmol/m2/min/s-Ins. NEFA =
non-esterified fatty acids. Number of Norwegians and Pakistanis were: during
the low step, n = 19 and 16, respectively. During the high step, n = 19 and 14,
respectively, and for NEFA measurements, n = 13 and 15, respectively.
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leptin (rs = 0.59, p = 0.006). In the Pakistani group, IL-1RA
neither correlated to ISI, nor to leptin (rs = 0.14, p =
0.593), but correlated positively to waist circumference.
Discussion
In the present study we found significant differences in
insulin sensitivity, measured by the euglycemic, hype-
rinsulinemic clamp, between young adult Norwegian
and Pakistani patients with T2DM. There were also eth-
nic differences in diabetes duration and HbA1c, even in
this young patient population, demonstrating longer
duration of diabetes and poorer glycemic control in the
Pakistani group. These differences, however, did not
explain the lower insulin sensitivity in the Pakistani
group per se, since neither HbA1c nor diabetes duration
were significantly associated with the ethnic differences
found in insulin sensitivity in adjusted multiple regres-
sion analyses.
Furthermore, we demonstrated a different relationship
between insulin sensitivity and BMI in the two groups.
Although obesity is clearly an important factor in insulin
resistance, BMI was a poor marker of metabolic distur-
bances in the Pakistani patients. Whereas Pakistani pa-
tients were all quite insulin resistant regardless of BMI,
among the Norwegian patients there was a strong ne-
gative correlation between BMI and insulin sensitivity.
To our knowledge, this is the first study, using the
euglycemic clamp to measure insulin sensitivity, to show
such ethnic differences in subjects with T2DM. Our re-
sults support and expand previously published results
obtained in healthy South Asian immigrants [20,21].
NEFA are normally suppressed by hyperinsulinemia.
There is evidence that this suppression is impaired in
T2DM [22], although this has not been found by all
authors [23]. Our study shows similar fasting NEFA
values between the two ethnic groups, but significantly
slower NEFA suppression in the Pakistani group, despite
higher fasting and end-clamp serum insulin levels. Some
evidence of ethnic differences, both in fasting NEFA
levels and degree of suppression by hyperinsulinemia,
has previously been shown in non-diabetic subjects [24].
Other authors, however, found no difference in NEFA
suppression according to ethnicity [25]. Our findings
further support that impaired insulin sensitivity affects
lipid metabolism more severely in Pakistani patients as
compared to Norwegian patients with T2DM.
It is noteworthy that leptin and IL-1RA were differently
related to insulin sensitivity in the two ethnic groups.
T2DM is now regarded as a disorder characterized by
non-resolving inflammation. IL-1, released though acti-
vation of Nod-like receptor protein 3 (NLRP3) infla-
mmasomes, seems to play an important role in the
inflammatory processes [26]. Il-1RA is considered an anti-
inflammatory cytokine, that antagonizes IL-1β and IL-1α,
and is elevated, at least in part, in response to elevation of
these inflammatory cytokines. An early study showed de-
creased IL-1RA levels in type 2 diabetes [27], and it has
been demonstrated that Leptin decreases β-cell produc-
tion of IL-1RA, down-regulating IL-1RA expression in
pancreatic β-cells in type 2 diabetes [28]. However, more
recent studies have shown high levels of IL-1RA in obes-
ity, correlating with BMI, insulin resistance and serum
Table 3 Multiple regression analyses of insulin sensitivity
Variable Adjusted effect β 95% CI p-value Adjusted effect β 95% CI p-value
Model A: LogISI40 LogGIR40
Ethnicity −0.335 (−0.588, -0.081) 0.012 −0.210 (−0.429, 0.010) 0.060
Sex −0.726 (−1.129, -0.322) 0.001 −0.455 (−0.804, -0.106) 0.013
% body fat −0.061 (−0.084, -0.037) <0.001 −0.044 (−0.065, -0.024) <0.001
Model A + BMI 0.008 (−0.015, 0.031) 0.464 0.002 (−0.017, 0.022) 0.803
Model A + HbA1c −0.009 (−0.095, 0.078) 0.835 −0.038 (−0.111, 0.036) 0.300
Model A + Diabetes duration −0.001 (−0.028, 0.026) 0.941 0.005 (−0.019, 0.028) 0.697
Model B: LogISI400 Log GIR400
Ethnicity −0.186 (−0.333, -0.040) 0.014 −0.117 (−0.229, -0.005) 0.042
% body fat −0.009 (−0.017, 0.000) 0.040 −0.007 (−0.013, 0.000) 0.043
Model B + Sex −0.163 (−0.394, 0.068) 0.158 −0.081 (−0.262, 0.101) 0.369
Model B + BMI 0.005 (−0.007, 0.018) 0.378 0.005 (−0.004, 0.014) 0.295
Model B + HbA1c 0.005 (−0.045, 0.055) 0.829 −0.013 (−0.051, 0.025) 0.493
Model B + Diabetes duration −0.008 (−0.023, 0.007) 0.304 −0.007 (−0.019, 0.005) 0.231
Table 3: Dependent variables in model A: LogISI40 or LogGIR40. Constant for Log ISI40 = 4.428. R
2: 0.55. Constant for LogGIR40 = 4.464. R
2: 0.48. Reference group for
ethnicity = Norwegians, for sex = women. Variables excluded from final models: BMI, HbA1c(NGSP) and diabetes duration.
Dependent variables in model B: LogISI400 or LogGIR400. Constant for Log ISI400 = 1.650. R
2: 0.29. Constant for LogGIR400 = 3.558. R
2: 0.24. Variables excluded from
final models: sex, BMI, HbA1c and diabetes duration. In bold: p < 0.05.
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leptin levels, and increased production of IL-1RA in adi-
pose tissue in obese humans [29-31]. Subjects with im-
paired glucose tolerance have higher levels of IL-1RA [32],
and in two prospective cohort studies, IL-1RA was found
to be elevated several years before diabetes diagnosis, and
significantly predicted incident diabetes [33,34]. Whether
this represents a counteracting mechanism in response to
IL-1, which circulates at much lower levels in plasma and
is more difficult to detect in clinical samples, is at present
unclear. In our study, leptin as well as IL-1RA was nega-
tively associated with insulin sensitivity in the Norwegian,
but not the Pakistani patients. Leptin and IL-1RA corre-
lated with BMI in both groups, and with waist circumfer-
ence in the Pakistani group only. These findings, together
with the different relationship between insulin sensitivity
and BMI demonstrated in our two groups, suggest that
there may be important differences in the relationship
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Figure 1 Relation between ISI40, BMI and waist circumference.
Relation of insulin sensitivity, expressed as ISI40, to a) body mass
index (BMI) and b) waist circumference in Norwegian (black
diamonds) and Pakistani (white circles) patients with type 2 diabetes.
Solid regression lines represent Norwegian patients and dashed lines
represent Pakistani patients. Spearman’s Correlation coefficients (rs)
and p-values for each correlation are presented for both ethnicities.
In a) the correlations have been performed both including and
omitting the outlier (BMI 59). They give approximately the same
result, and the outlier is excluded in the rs presented, but shown in
the scatterplot.
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Figure 2 Suppression of NEFA during euglycemic clamp.
Non-esterified fatty acid (NEFA) values have been standardized, with
fasting values set to 1.0. The figure shows standardized mean (SD)
values of NEFA during the first 120 minutes of the low step
euglycaemic clamp, for both patient groups. Norwegian patients are
shown in black diamonds with solid lines. Pakistani patients are
shown in white circles with dashed lines. *p < 0.05.
Table 4 Adipokines and markers of inflammation
Norwegians Pakistanis p-value
Adiponectin (μg/ml) 4.6 (4.4) 3.3 (3.4) 0.15
Leptin (pmol/l) 950 (1043) 907 (1014) 0.89
IL-6 (pg/ml) 1.18 (1.19) 1.07 (2.18) 0.43
hsCRP (pg/ml) 2.31 (3.48) 2.45 (2.46) 0.63
IL-1RA (pg/ml) 62.75 (98.10) 45.90 (103.95) 0.36
sTNF-R1 (ng/ml) 1.04 (0.20) 0.92 (0.31) 0.14
Table 4: Data are presented as median (interquartile range), and comparisons
are made using the Mann–Whitney U test. Nor = Norwegian patients. Pak =
Pakistani patients.The number of Nor/Pak were: for adiponectin and leptin,
n = 21/18. For IL-6, hsCRP and IL-1RA, n = 20/17, and for sTNF-R1, n = 20/16.
IL-6 = interleukin-6, hsCRP = high sensitive C-reactive protein, IL-1RA =
interleukin-1 receptor antagonist, sTNF-R1 = soluble tumor necrosis
factor-receptor 1.
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between obesity, insulin sensitivity, and the effect and/or
regulation of these signal molecules between the two eth-
nic groups. As leptin is known to correlate mainly to
superficial abdominal adipose tissue [35,36], our findings
could indicate that ethnic differences exist in the meta-
bolic activity of the different compartments of abdominal
adipose tissue.
The main strengths of our study include thorough pa-
tient examinations with gold standard methods for
measurement of insulin sensitivity, and using two steps
of hyperinsulinemia. The difference in HbA1c and dia-
betes duration between the two patient groups may be
regarded as a weakness. However, these differences were
also present in patients who were not included in the
study, and have been demonstrated in several other
studies [10-12]. Thus, an attempt to match for these pa-
rameters could in our opinion have created a selection
bias. It can nevertheless be regarded as a limitation to
our study that patients were recruited from a popula-
tion referred to hospital outpatient diabetes clinics, and
that sample size was limited, increasing the risk of type
II statistical errors. Recruitment of patients, especially
the Pakistani patients, proved challenging, which ex-
plains why only 20% of the invited patients participated.
While a larger and more representative cohort would
have strengthened our study, we note that the ethnic
differences in insulin sensitivity showed consistent pat-
terns for all four estimates of insulin sensitivity. This
also corresponds well with the clinical picture of higher
diabetes prevalence and poorer glycemic control appar-
ent in South Asian populations. We did not measure
endogenous glucose production during the euglycemic
clamp, and our glucose infusion rates may therefore
underestimate the true peripheral glucose uptake, at
least during the low insulin infusion level. Lastly, body
composition was measured by BIA, which may be less
accurate than dual x-ray absorptiometry, computed
tomography or magnetic resonance imaging. BIA is,
however, an inexpensive and accessible way of estimat-
ing body composition, which is gaining use in clinical
practice.
Conclusions
In this study of Norwegian and Pakistani patients with
T2DM we found significant differences in insulin sensi-
tivity and the relationship between insulin sensitivity and
obesity markers, which may impact on our understand-
ing of the pathogenic mechanisms that place Pakistani
subjects at higher risk of developing T2DM. Further
studies are needed to elucidate a possible relationship
between insulin sensitivity, various adipose tissue com-
partments and adipokines and related molecules in vari-
ous ethnic groups.
Additional files
Additional file 1: Table showing. Further clinical characteristics of
patients according to ethnic group.
Additional file 2: Table showing. Correlations between parameters of
insulin sensitivity, anthropometry, adipokines and inflammation.
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Additional file 1: Further clinical characteristics of patients according to ethnic group.
Norwegians Pakistanis 
n = 21 n = 18
Diabetes treatment n(%)
Lifestyle ± OAD / Insulin ± OAD 11 (52%) / 10 (48%) 5 (28%) / 13 (72%)
Other medications
Statins 10 (48%) 4 (22%)
Blood pressure lowering agents 8 (38%) 7 (39%)
Self reported complications
Macrovascular 2 (10%) 3 (17%)
Retinopathy 2 (10%) 3 (17%)
Nephropathy or microalbuminuria 2 (10%) 6 (33%)
Neuropathy 1 (5%) 3 (17%)
Diabetic foot 1 (5%) 0 (0%)
Others (ED, fatty liver, periodontitis) 5 (24%) 6 (33%)
Co-morbidities
Astma/COPD 4 (19%) 4 (22%)
Psychiatric conditions 4 (19%) 1 (6%)
GI disease 5 (24%) 2 (11%)
Other endocrine disorders 2 (10%) 3 (17%)
Smoking 10 1
Parity in women 
0-2 11 4
3-5 0 5
Supplementary Table 1: Parity was defined as the number of live-born children each woman had given 
birth to. OAD = oral antidiabetic drugs. ED = erectile dysfunction. COPD = chronic obstructive 
pulmonary disease. GI = gastro-intestinal. 
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2Abstract
Immigrants from South Asia to Western countries have a high prevalence of type 2 diabetes 
mellitus (T2DM) associated with obesity. We investigated the relationship between diabetes 
and adipose tissue distribution in a group of younger T2DM subjects from Norway and 
Pakistan. Eighteen immigrant Pakistani and 21 Norwegian T2DM subjects (age 29-45, 49% 
men) were included. They underwent anthropometrical measurements including bioelectrical 
impedance analysis, CT scans measuring fatty infiltration in liver and adipose and muscle 
tissue compartments in mid-abdomen and thigh, a euglycemic clamp, and blood samples for 
serum insulin and plasma glucose, adipokines and inflammation markers. Adipose tissue 
distribution was similar in Norwegians and Pakistanis. Pakistanis, but not Norwegians, 
showed a negative correlation between insulin sensitivity and visceral adipose tissue (VAT, rs
= -0.704, p = 0.003). Subcutaneous adipose tissue (SAT) correlated to leptin in both 
Pakistanis and Norwegians (rs = 0.88, p < 0.001 and 0.67, p = 0.001). SAT also correlated to 
C-reactive protein (CRP) in the Pakistanis only (rs = 0.55, p = 0.03), and superficial SAT to 
Interleukin-1 receptor antagonist (IL-1RA) in Norwegians only (rs = 0.47, p = 0.04). In 
conclusion, despite similar adipose tissue distribution in the two groups Pakistanis were more 
insulin resistant, with a negative correlation of VAT to insulin sensitivity, not present in 
Norwegians. The correlation of adipose tissue to Leptin, CRP and IL-1RA showed ethnic 
differences. 
Key words: Anthropometry; C-reactive protein; Computed tomography; Immigrants; Insulin 
resistance; Interleukin 1-receptor antagonist; Leptin; South Asia; Subcutaneous adipose 
tissue; Visceral adipose tissue.
3Introduction
Immigrants from South Asia to Western countries show increased insulin resistance [1] and a 
high prevalence of type 2 diabetes mellitus ( T2DM) [2;3]. The association between insulin 
resistance and obesity is well established. However, several reports indicate that commonly 
used methods of anthropometric measurements, like the body mass index (BMI), may be 
inadequate as indicators of metabolic risk in South Asians, who seem to develop insulin 
resistance and  T2DM at levels of BMI that are considered low risk in the Western population 
[4;5].
Body composition can be measured using dual x-ray absorptiometry (DXA) or bioelectrical 
impedance analysis (BIA). However, these methods discriminate poorly between the various 
abdominal adipose tissue compartments such as subcutaneous (SAT) and visceral adipose 
tissue (VAT). Using computed tomography (CT) or magnetic resonance imaging (MRI), the 
adipose tissue compartments can be measured more accurately [6]. Previous studies have 
indicated that abdominal SAT and VAT are differently related to metabolic risk [7], and that 
VAT, and possibly deep subcutaneous adipose tissue (DSAT), is closely related to insulin 
resistance [8]. Increased fatty infiltration in the liver is also associated with overall insulin 
resistance [9].
Obesity and insulin resistance are accompanied by low-grade systemic inflammation with 
increased plasma levels of inflammatory markers, in part released from adipose tissue. Recent 
studies have suggested that the various adipose tissue compartments may differ in their 
inflammatory potential [10-12] in addition to their differing relation to insulin resistance. 
4The aim of this study was to investigate i) possible differences in the abdominal adipose tissue 
distribution between T2DM subjects from Norway and Pakistan, ii) whether ethnic 
differences in insulin resistance could be explained by differences in body composition, and 
iii) whether possible ethnic differences in insulin resistance and body composition could be 
related to plasma levels of inflammatory markers. 
5Materials and Methods
Ethics
The study was approved by the Eastern Norway Regional Committee for Medical and Health 
Research Ethics, and conformed to the Helsinki declaration. Informed written consent was 
obtained from each participant prior to any study related procedure. 
Patients
The study population has previously been described [13]. Briefly, 18 Pakistani and 21 
Norwegian patients (49% men), aged 29 to 45 years, with confirmed T2DM, were recruited 
from two hospital out-patient clinics, at Lovisenberg Deaconess Hospital and Aker University 
Hospital in Oslo. Clinical characteristics of the two ethnic groups are shown in Table I. 
Anthropometrical measurements
Height and weight were measured with participants wearing light clothing and no shoes. BMI 
was calculated as weight in kg/(height in m)2. Waist and hip circumferences were assessed 
with a tape measure with spring scale to ensure equal traction at every measurement, 
measuring at mid point between the lowest rib margin and the iliac crest, and at the level of 
the major trochanter, respectively. BIA was performed on 17 of the Norwegian and 14 of the 
Pakistani patients, on a Tanita Body Composition Analyzer BC-418 (Tokyo, Japan), 
providing measurements of percentage total body fat (%TBF), body fat mass in kilograms 
(BFM) and fat free mass in kilograms (FFM). All subjects were fasting and had voided urine 
before measurements. 
Computed tomography measurements
CT was performed using a CT Somatom (Erlangen, Germany) with the patient examined in a 
supine position, arms extended above the head. Three single axial scans were performed 
6without intra-venous contrast medium through i) the liver and the spleen, at the level of Th12, 
ii) the mid-abdomen, 10 cm above L4/L5 in men and 5 cm above L4/L5 in women (Figure 
IA) [14], and iii) the thighs, at mid-distance between the anterior-superior iliac spine and the 
upper margin of the patella. CT parameters were 120 kV, 100 mAs, and slice thickness 4 mm. 
The dicom images were analysed using Osirix v 3.2.4, 32 bit. 
The fat content of the liver was based on attenuation values in Hounsfield Units (HU). The 
liver-spleen ratio (LS-ratio) was calculated based on the mean of three measurements in the 
liver (2 right lobe and 1 left lobe) and two measurements in the spleen with a region of
interest (ROI) 80 mm2 (Figure IB). In mid-abdomen, the circumferences for subcutaneous 
adipose tissue (SAT) were tracked for both superficial (SSAT) and deep subcutaneous 
adipose tissue (DSAT) compartments, divided by the superficial fascia [15]. The visceral 
adipose tissue (VAT) compartment was measured by tracking the inner abdominal 
circumference, and measuring pixels with fat highlighted between -30 and -190 HU (Figure 
IC and D). The right thigh was selected for measuring thigh SAT and muscle compartments 
(Figure IE and F). 
Euglycemic clamp
The euglycemic clamp method has previously been described [13]. Briefly, the patients 
underwent a two-step euglycemic, hyperinsulinemic clamp, using a modified version of the 
method originally described by De Fronzo et al. [16]. Human insulin (Actrapid®, Novo 
Nordisk, Copenhagen, Denmark) 300 mU/mL and Glucose 200 mg/mL were infused through 
a teflon catheter in a vein at the left elbow of the patient. Insulin was diluted in NaCl 0.9 %, 
after having first added 2 mL of the patients own blood, to avoid insulin sticking to the walls 
of the bag. All blood samples were drawn from a teflon catheter in a vein at the right elbow, 
kept open by a slow infusion of NaCl 0.9 %. The right arm was kept at 37°C by a heating 
sleeve connected to a thermal control unit (Swetron AB, Veddestad, Sweden), to arterialise
7blood samples. Two successive clamp steps of 40 and 400 mU/m2/min of insulin were
performed, with a minimum duration of 100 minutes, and at least 30 minutes of stable 
euglycemia for each clamp step. The body surface area was calculated using Mostellers 
equation [17]. Plasma glucose was measured every five minutes using a OneTouch Ultra 
glucose measuring device (LifeScan, Milpitas, CA), with control measurements every 30
minutes by the glucose oxidase method, on a Glucose Analyzer II (Beckman Instruments, 
)XOOHUWRQ&$7KHJOXFRVHLQIXVLRQUDWH*,5LQȝPROP2/min was calculated for both 
clamp steps. The Insulin Sensitivity Index (ISI) was expressed as the ratio of the GIR to the 
prevailing mean serum insulin levels at the end of each clamp step ([GIR/I] x 100). Data 
presented here are from the first step of the clamp. Two Norwegian and two Pakistani patients 
did not attain euglycemia during the first step of the clamp, and were excluded from this part 
of the clamp analyses. After excluding these patients, there were 46% men in the first step of 
the clamp.
Blood samples
Fasting plasma glucose was measured by the glucose oxidase method on a Glucose Analyzer 
II (Beckman Instruments). Serum insulin was analysed using the radioimmunoassay (RIA) 
kit, formerly from Linco Research, presently available from Millipore Corp. (Billerica, MA). 
Plasma levels of adiponectin and leptin were analysed using RIA kits from Millipore Corp. 
(Billerica, MA),(also formerly from Linco Research). Plasma high sensitive C-reactive 
protein (hsCRP) was measured using a DuoSet ELISA kit from R&D Systems (Minneapolis, 
MN). Plasma interleukin-1 receptor antagonist (IL-1RA) was measured using CytoSet from
Invitrogen Corporation (Carlsbad, CA), with streptavidin-horseradish peroxydase from R&D 
Systems. Plasma measurement of interleukin-6 (IL-6) was performed using a High Sensitivity 
ELISA kit from Abcam plc. (Cambridge, UK)
8Statistical analyses
Data are presented as mean ± SD or median [inter-quartile range] unless otherwise specified. 
We analysed non-normally distributed data using non-parametric methods, or log-
transformed, as appropriate. Student’s t tests or Mann Whitney U tests were used for 
comparison of continuous variables between groups. For comparison of categorical data 
between patient groups, the Chi square test for independence was used. Spearman’s 
correlation coefficient (rs) was used. Multiple linear regression analyses were performed, with 
log-transformation of parameters when needed, to ensure no violation of the assumptions of 
normality, linearity and homoscedasticity. A two-sided p-value <0.05 was regarded as 
significant, but owing to the large number of comparisons, particular attention should be 
directed towards analyses where p-values are <0.01. Statistical analyses were performed with 
SPSS 19.0 for windows (SPSS Inc., Chicago, IL).
Results
Adipose tissue distribution
The Norwegians had higher weight, BMI, BFM and FFM than the Pakistanis, but there was 
no significant difference in the % TBF (Table I). 
Liver fat infiltration and abdominal and thigh adipose tissue compartments did not differ 
between the two ethnic groups (Table II). The relative size of VAT as determined by the 
VAT/SAT ratio, was significantly smaller in women than in men (0.49 [0.35] vs. 1.26 [0.84], 
p<0.001), but again, there was no ethnic difference. For women, abdominal and thigh muscle 
compartments were significantly larger in the Norwegian group, while for men, there was 
only a tendency towards larger abdominal muscle compartment in the Norwegians (Table II). 
SAT was found to correlate well to several anthropometrical markers of obesity, such as BMI, 
waist circumference and %TBF in both groups. VAT on the other hand, correlated less well to 
9BMI and waist circumference, with particularly weak correlations in the Norwegian group. 
Moreover, VAT was paradoxically, negatively correlated to %TBF in the Norwegian group  
with no significant correlation in the Pakistani group (Table III).
Insulin sensitivity
Insulin sensitivity (ISI40) was negatively correlated to VAT and positively correlated to liver 
attenuation and LS-ratio, but not to SAT, in the total patient group. However, when analysing
each ethnic group separately, the negative association with VAT and liver fat was present in 
the Pakistani group while it was not significant in the Norwegian group (Table IV). Using
multiple regression analysis examining predictors of insulin sensitivity, we found that 38.6 % 
of LogISI40 variation was explained by the combination of VAT (p<0.001), sex (p=0.015) and 
ethnicity (p=0.046), (model significance: p=0.002). The total DSAT+VAT compartment was 
also significantly correlated to ISI40, and again, this did reach statistical significance in the 
Pakistani but not in the Norwegian group (Table IV). In line with this, the correlation between 
DSAT+VAT and ISI40 became stronger (p=0.001) when adjusting for ethnicity (p=0.023) in a 
multiple regression analysis with logISI40 as dependent variable (model significance: 
p=0.003, R2 =0.31).
Adipokines and inflammatory markers
Plasma levels of leptin, CRP and IL-1RA showed significant correlations with adipose tissue 
compartments, while no association was shown for adiponectin or IL-6 (Table V). Plasma 
levels of leptin were highly positively correlated to abdominal and thigh SAT in both groups,
with the strongest correlations in the Pakistani group. In fact, in a multiple regression analysis 
exploring predictors of plasma leptin, we found that 77.8 % of the variation in leptin was 
explained by SSAT (p<0.001), sex (p<0.001) and ethnicity (p=0.046) (model significance: 
10
p<0.001). Moreover, CRP was positively correlated to abdominal SAT in the Pakistani group, 
and IL-1RA to abdominal and thigh SAT in Norwegian group only. 
Discussion
In this study, we report both ethnic similarities and differences in the distribution of adipose 
and muscle tissue, as well as their relations to insulin sensitivity and inflammatory markers.
The Norwegian and Pakistani groups showed no significant differences in the areas of adipose 
tissue compartments measured by CT in abdomen or thigh. However, we observed ethnic 
differences in how abdominal adipose tissue compartments such as SSAT, DSAT and VAT 
related to insulin sensitivity and inflammatory markers. VAT appeared to be more 
metabolically active in the Pakistani than in the Norwegian group, displaying strong negative 
correlations to insulin sensitivity. In addition, an association between CRP and abdominal 
SAT was only seen in the Pakistani group, suggesting a stronger link between SAT and 
inflammation in Pakistanis with T2DM as compared with the Norwegians. 
The significant positive correlations of CRP to SAT compartments, but not to VAT in our 
Pakistani patients are at variance with some previous reports [11;12]. This may be due to the 
higher BMI, %TBF and HbA1c values in both our ethnic groups than those reported in other 
studies, making comparisons difficult. In a cohort of severely obese subjects, CRP was found 
to be a non-specific marker of obesity, and not related to specific adipose tissue compartments 
or metabolic dysregulation like the metabolic syndrome, T2DM or non-alcoholic steato-
hepatitis [18]. SAT in our study correlated better than VAT to general measurements of 
obesity, thus possibly explaining these findings in our Pakistani group. Nonetheless, CRP is a
reliable down-stream marker of inflammation, and the positive correlation of CRP to SAT in 
the Pakistani group suggests a more inflammatory potential in SAT in the Pakistani group.
11
We found similar abdominal adipose tissue distribution in the Pakistani and Norwegian 
groups. Recently, Lear and co-workers demonstrated that healthy South Asian men and 
women had higher levels of both SAT and VAT than a similar group of subjects of European 
ancestry [19]. The same authors have however previously shown that the ethnic differences in 
VAT between the South Asians and Europeans in this cohort were only evident when waist 
circumference was lower than 105 cm [20]. Other authors have found no ethnic differences in 
adipose tissue distribution, at least in men [21;22]. In our study population the mean waist 
circumferences were wider than 105 cm in both ethnic groups, and BMI was higher than in 
the studies mentioned (Table I). The higher degree of adiposity in our study, where the 
subjects also had established T2DM, could therefore have attenuated ethnic differences in 
VAT, and possibly also in SAT. 
Leptin levels were strongly and positively correlated to areas of SAT in both ethnic groups, as 
expected. This was also seen for IL-1RA in the Norwegian group. Leptin has been shown to 
induce monocyte expression of IL-1RA [23], and increased levels of IL-1RA are correlated to 
the hyperleptinemia of obesity [24]. IL-1RA has been shown to correlate to SAT and 
especially to VAT [25]. Increasing IL-1RA levels have also been associated with the 
development of T2DM [26]. In our patients, IL-1RA, like leptin, correlated positively to SAT 
in abdomen and thigh in the Norwegian, but not the Pakistani group. There was no significant 
correlation of IL-1RA to VAT. Our results may indicate that IL-1RA is a more important 
factor in the Norwegian than in the Pakistani group. However, due to relatively small numbers 
included, conclusions should be drawn with care..
In our Norwegian group, the adipose tissue compartments seemed to be less important for 
determining insulin sensitivity. The mean age at diagnosis of T2DM in subjects from South 
12
Asia living in Norway has previously been found to be more than 10 years lower than in 
ethnic Norwegians [27]. We might speculate that by having selected young Norwegian T2DM 
subjects these could have a stronger genetic predisposition to diabetes. Obesity might 
therefore be of somewhat less importance for the development of T2DM in the Norwegian 
group. The Pakistani subjects on the other hand, were closer in age to the average Pakistani 
T2DM patient in Norway. The negative correlation between insulin sensitivity and VAT, seen 
only in the Pakistani group, may also reflect genuine ethnic differences in the composition 
and metabolic character of VAT, with VAT being more metabolically active in Pakistanis 
than in Norwegians.
The strengths of this study include employing the two-step euglycemic, hyperinsulinemic 
clamp for measuring insulin sensitivity, and having both CT and BIA measurements of body 
composition. The groups we have studied are of restricted numbers, and this constitutes a 
limitation, increasing the risk of not being able to detect small but possibly important 
differences. Furthermore, we report many statistical tests without correction for multiple 
testing, with the risk of reporting p-values <0.05 by chance. We therefore focused on the most 
robust statistical findings in our discussion and conclusions, and have taken care to give the 
exact p-values throughout the manuscript, to facilitate the possibility for the reader to judge. 
By recruiting patients from hospital out-patient clinics only, there may be a selection bias 
towards including subjects with T2DM that is not easily treated in general practice, and the 
findings should be interpreted in this context.
In conclusion, we report that in spite of similar adipose tissue distribution in the Norwegian 
and Pakistani groups, there is evidence of ethnic differences in the importance of adipose 
tissue distribution for insulin sensitivity, where visceral adipose tissue seems to be especially 
13
important in the metabolic dysregulation in Pakistanis. We have also found differences in the 
relationship between adipose tissue distribution and some adipokines and markers of 
inflammation, although further investigation in this field is needed. 
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Table III: Correlations of adipose tissue compartments to anthropometrical 13
measurements14
SAT VAT
Nor Pak Nor Pak
BMI rs 0.87 0.74 -0.02 0.46
p < 0.001 0.001 0.94 0.06
Waist circumference rs 0.59 0.72 0.23 0.45
p 0.006 0.001 0.34 0.07
% TBF rs 0.72 0.92 -0.57 0.05
p 0.001 < 0.001 0.017 0.88
15
Table III: Spearman’s correlation coefficients (rs) for SAT (subcutaneous adipose 16
tissue) and VAT (visceral adipose tissue). BMI (body mass index), %TBF (percentage 17
total body fat). Nor = Norwegians, Pak = Pakistanis.18
19
17
Table IV: Correlations of adipose tissue compartments to the Insulin Sensitivity Index in 
Norwegian and Pakistani patients with  T2DM
ISI40
Tot n=34 Nor n=19 Pak n=15
SSAT rs -0.253 -0.308 -0.339
p 0.150 0.199 0.216
DSAT rs -0.068 -0.160 -0.141
p 0.702 0.514 0.615
VAT rs -0.424 -0.249 -0.704
p 0.013 0.304 0.003
DSAT+VAT rs -0.432 -0.338 -0.781
0.011 0.157 0.001
Liver Att.* rs 0.404 0.319 0.427
p 0.016 0.182 0.099
LS-ratio * rs 0.401 0.329 0.389
p 0.017 0.169 0.137
Table IV: Spearman’s correlation coefficients (rs) for SSAT (superficial subcutaneous 20
adipose tissue), DSAT (deep subcutaneous adipose tissue), VAT (visceral adipose 21
tissue), and Liver Att. (Liver attenuation). Correlation coefficients with p-values < 0.05 22
are in bold. * Total n=35, Pakistani n=16. Tot = total, Nor = Norwegians, Pak = 23
Pakistanis24
25
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Figure I: Computed tomography measurements in Norwegian and Pakistani 31
patients with T2DM32
33
Figure I: A) Abdominal scanogram marked with the levels of the two axial CT scans,34
with the most cranial through the liver and spleen (L), and the caudal scan 10 cm above35
L4/L5 in men (M) or 5 cm above L4/L5 in women (W). B) Axial CT scan showing36
three regions of interest (ROI) in the liver and two in the spleen, for measurement of 37
attenuation in Hounsfield Units. C) and D) Axial mid-abdominal CT-scans showing 38
21
tracking of fat and muscle compartments and highlighting of VAT in a Norwegian 39
woman (C) and Pakistani woman (D) with large and small abdominal muscle areas40
respectively. E) and F) CT-scans through thighs in a Norwegian (E) and a Pakistani (F)41
woman showing the tracking of fat and muscle compartments. 42
43
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Characteristics of Glucose Metabolism in Nordic and
South Asian Subjects with Type 2 Diabetes
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Abstract
Background: Insulin resistance and type 2 diabetes are more prevalent in people of South Asian ethnicity than in people of
Western European origin. To investigate the source of these differences, we compared insulin sensitivity, insulin secretion,
glucose and lipid metabolism in South Asian and Nordic subjects with type 2 diabetes.
Methods: Forty-three Nordic and 19 South Asian subjects with type 2 diabetes were examined with intra-venous glucose
tolerance test, euglycemic clamp including measurement of endogenous glucose production, indirect calorimetry
measuring glucose and lipid oxidation, and dual x-ray absorptiometry measuring body composition.
Results: Despite younger mean 6 SD age (49.769.4 vs 58.368.3 years, p = 0.001), subjects of South Asian ethnicity had the
same diabetes duration (9.365.5 vs 9.667.0 years, p= 0.86), significantly higher median [inter-quartile range] HbA1c (8.5 [1.6]
vs 7.3 [1.6] %, p= 0.024) and lower BMI (28.764.0 vs 33.264.7 kg/m2, p,0.001). The South Asian group exhibited
significantly higher basal endogenous glucose production (19.1 [9.1] vs 14.4 [6.8] mmol/kgFFM?min, p= 0.003). There were
no significant differences between the groups in total glucose disposal (39.1620.4 vs 39.2617.6 mmol/kgFFM?min, p= 0.99)
or first phase insulin secretion (AUC0–8 min: 220 [302] vs 124 [275] pM, p= 0.35). In South Asian subjects there was a tendency
towards positive correlations between endogenous glucose production and resting and clamp energy expenditure.
Conclusions: Subjects of South Asian ethnicity with type 2 diabetes, despite being younger and leaner, had higher basal
endogenous glucose production, indicating higher hepatic insulin resistance, and a trend towards higher use of
carbohydrates as fasting energy substrate compared to Nordic subjects. These findings may contribute to the
understanding of the observed differences in prevalence of type 2 diabetes between the ethnic groups.
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Introduction
The prevalence of type 2 diabetes (T2D) varies between
different ethnic groups, and is known to be high in South Asians
(SA) in their countries of origin, particularly in urban areas, but
also after migration to Western countries [1]. Several theories as to
why SA are especially prone to insulin resistance and T2D have
been proposed. Among these, the adipose tissue overflow
hypothesis proposes that SA have smaller superficial subcutaneous
adipose tissue compartments for fat storage compared to Western
Europeans. Hence, in situations of energy excess, fat is deposited
in the more metabolically active deep subcutaneous and visceral
adipose tissue compartments [2]. The metabolic inflexibility
theory proposes that the normal switch in energy substrate
between high lipid oxidation in the fasting state and high glucose
oxidation in the post-prandial state is impaired in T2D. This
results in accumulation of intramuscular lipids and increased
plasma glucose values [3]. A third suggested mechanism involves
the theory that SA have lower resting energy expenditure (REE)
than Western Europeans, and therefore are more prone to obesity
and insulin resistance. This theory is disputed, where some argue
that the lower REE is due to differences in body composition and
not ethnicity [4,5].
Although insulin resistance and T2D have been much studied in
the SA population during recent years, few studies have used gold
standard methods for the measurement of insulin resistance, and
to our knowledge, no previous studies have reported endogenous
glucose production (EGP) in SA T2D subjects.
In order to gain insights into possible explanations for the
differences in prevalence of T2D between the two populations, we
analysed baseline data from a vitamin D intervention trial in
subjects with T2D and Nordic (NOR) or SA origin, all living in
Oslo, Norway. Insulin sensitivity, glucose and fat oxidation, and
insulin secretion was measured. The subjects all had serum levels
of 25-hydroxyvitamin D #50 nM.
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The primary aims of this study were to: 1) Explore possible
differences in fasting and clamp hyperinsulinemic glucose metab-
olism, 2) Explore possible differences in insulin secretion, 3)
Explore possible differences in energy expenditure, and 4) Assess
possible associations between insulin sensitivity and -secretion, and
vitamin D status.
Methods
Ethics
All participants gave informed written consent prior to any
study related procedure. The study was approved by the South-
Eastern Norway Regional Committee for Medical and Health
Research Ethics, and conformed to the Declaration of Helsinki.
Subjects
Sixty-two patients with T2D and 25-hydroxyvitamin D
#50 nM, were recruited from our out-patient clinic, from general
practice, from posters in the hospital lobby and in pharmacies, and
from advertisements in local newspapers. Men and women with
T2D, from the Oslo area in Norway, above 18 years of age, of
Nordic or South Asian origin (born in a South Asian country and/
or with both parents of South Asian origin) were eligible,
regardless of type of anti-diabetic treatment. Full inclusion and
exclusion criteria are displayed in Table 1. In total, 190 patients
were screened. Sixty-two patients met with the inclusion criteria
and were recruited, and 61 patients underwent initial intra-venous
glucose tolerance tests (IVGTT) and clamp procedures. The
Nordic group consisted of 40 Norwegians, 2 Danes and 1 Swede.
The South Asian group consisted of 11 Pakistanis, 7 Sri Lankans
(all Tamil) and 1 Indian. All but one of the South Asian
participants were first generation immigrants. One Norwegian
patient was excluded due to severe difficulties in getting
intravenous access. Table 2 shows important characteristics of
the two ethnic groups.
Anthropometrics
Height to the nearest 0.1 cm and weight to the nearest 0.1 kg
were measured with participants wearing light clothing and no
shoes. Waist circumference was assessed with a flexible tape
measure with spring scale to ensure equal traction at every
measurement, measuring at mid-point between the lowest rib
margin and the iliac crest. The body surface area was calculated
using Mostellers equation [6]. Fat mass (FM) in kg, percentage
total body fat (%TBF), percentage truncal fat (% truncal fat) and
fat free body mass (FFM) in kg were measured by dual x-ray
absorptiometry (DXA) on a Lunar Prodigy from GE Healthcare.
IVGTT and Euglycemic Clamp
To enhance comparability of examinations, all patients were
asked to stop oral antidiabetic drugs for two days, and insulin for at
least 12 hours prior to examination. Patients were also asked to
refrain from strenuous physical exercise and alcohol intake during
these two days, and to arrive fasting for at least 10 hours, from the
night before the examination.
A teflon catheter was placed in a vein at each elbow. All
infusions were given in one vein, and all blood samples were
drawn from the other vein, which was kept open by a slow infusion
of NaCl 0.9%. The arm where blood samples were taken was kept
at 37uC by a heating sleeve connected to a thermal control unit
(Swetron AB, Veddestad, Sweden), to arterialize blood samples.
We performed an IVGTT followed by a euglycemic, hyperin-
sulinemic clamp, with estimation of endogenous glucose produc-
tion (EGP) using the stable isotope dilution method. A primed
(170 mg) continuous (1.7 mg/min) infusion of [6,6-2H2] glucose
(Cambridge Isotope Laboratories, Inc., Andover, MA) was
maintained throughout the experiment. After a 2-h tracer
equilibration period, the IVGTT was performed, with a ,1-
minute intravenous bolus injection of glucose 500 mg/mL, 0.3 g/
kg body weight. Blood samples were drawn for plasma glucose
concentration as well as serum insulin and C-peptide determina-
tion at 22, 0, 2, 4, 6, 8, 10, 15 and 30 minutes after glucose bolus
injection. Immediately following the IVGTT, a euglycemic,
hyperinsulinemic clamp was performed using a modification of
the method originally described by De Fronzo et al [7]. Human
insulin (ActrapidH, Novo Nordisk, Bagsvaerd, Denmark) was
diluted in 500 mL NaCl 0.9%, to 300 mU/mL, after having first
added 2 mL of the patients own blood, to avoid insulin sticking to
the walls of the bag, and 10 mmol KCl. Insulin was infused at a
rate of 80 mU/m2?min, after an initial bolus and 10 minute
priming infusion, determined by the patients pre-clamp plasma
glucose. The infusion was maintained for 2K hours or more, until
at least 30 minutes of stable euglycemia was obtained. When
plasma glucose reached euglycemia, a variable infusion of glucose
200 mg/mL enriched with 8 mg/g glucose of [6,6-2H2]-glucose
was continually adjusted to maintain euglycemia.
Plasma glucose was regularly measured on a Presicion Xceed
glucometer (Abbott Laboratories. Abbott Park, IL), with five-
minute intervals when the patient approached euglycemia.
Control measurements at least every 30 minutes were performed
on a Y.S.I 2300 STAT analyzer (Yellow Springs Instruments Inc,
Yellow Springs, OH). At the end of the clamp, three measure-
ments of serum insulin and fluoride/oxalate-plasma for analysis of
[6,6-2H2]-glucose were taken at ten-minute intervals. The glucose
infusion rate (GIR) in mmol/kg FFM?min was established.
IVGTT Calculations of Insulin Secretion
The Acute Insulin Response to glucose (AIRg) was calculated as
the incremental area under the curve (AUC) for insulin from time
0–8 minutes and 0–30 minutes.
Endogenous Glucose Production Calculations
Calculations of endogenous glucose production (EGP) at the
end of the basal equilibration period and during clamp euglycemia
were performed. Both were steady state for plasma glucose, with
only relatively small changes in glucose concentration and tracer
enrichment over time. Thus, steady state equations, where rate of
appearance equals rate of disappearance, have been applied for
the calculation of both EGP and total glucose disposal (TGD)
[8,9]. The EGP in the basal state was calculated as follows:
EGPbasal = I((Ei/Ep(basal)) –1), where I is the rate of [6,6-
2H2]-
glucose infusion (mmol/m2?min), Ei is the enrichment of the tracer
infusion in moles percent excess (mpe) and Ep(basal) is the mean
[6,6-2H2]-glucose enrichment in plasma (mpe) at the end of the
basal stabilisation period.
At the end of the euglycemic clamp, TGD was calculated as
follows: TGD= ((I ? Ei+GIR ? Em)/Ep(clamp)) – I, where GIR is the
exogenous glucose infusion rate (mmol/m2?min), Em is the
[6,6-2H2]-glucose enrichment (mpe) in the infused glucose, and
Ep(clamp) is the mean [6,6-
2H2]-glucose enrichment (mpe) in the
plasma samples taken during the last 30 minutes of the clamp
euglycemia. The EGP during clamp euglycemia, EGP-
clamp =TGD – GIR. Between subject and within subject coeffi-
cients of variation for plasma glucose levels in clamp steady state
were 10.0% and 4.6% respectively.
Type 2 Diabetes, Glucose Metabolism and Ethnicity
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Table 1. Inclusion and exclusion criteria.
Inclusion criteria:
Vitamin D deficiency defined as 25-hydroxyvitamin D ,50 nM
Patients with type 2 diabetes (negative anti-GAD and anti-IA2), including drug naı¨ve subjects, subjects using oral anti-diabetic medication and subjects on insulin
treatment
HbA1c ,11% (97 mmol/mol) at inclusion
Men and women $18 years
Nordic or South Asian ethnicity (from Pakistan, India, Bangladesh or Sri Lanka)
Antihypertensive medication, lipid lowering drugs, oral contraceptives, hormone replacement therapy, multivitamin supplements and nutritional supplements are
allowed
Exclusion criteria:
Systolic Blood Pressure $160 mmHg or Diastolic Blood Pressure $90 mmHg at inclusion
Significant renal disease or chronic renal impairment, GFR,30 mL/min
Significant liver disease or ASAT or ALAT .36 upper limit of normal
Malignancy during the last five years
Hypercalcemia at inclusion or a history of kidney stone disease
Pregnant or breastfeeding women
Chronic inflammatory disease in active phase or long term (.2 weeks) use of systemic corticosteroids last 3 months
Cardiovascular disease, defined as myocardial infarction, unstable angina pectoris or stroke, during the last 6 months prior to inclusion
Anemia defined as hemoglobin below current reference limits
BMI .45 kg/m2 or bariatric surgery performed during the last five years
Drug or alcohol abuse
Mental condition (psychiatric or organic cerebral disease) rendering the subject unable to understand the nature, scope and possible consequences of the study
Any medical condition that in the judgment of the investigator would jeopardize the subject’s safety
Main inclusion and exclusion criteria. GAD: glutamic acid decarboxylase, IA2: protein tyrosine phosphatase, GFR: glomerular filtration rate, ASAT: aspartate amino
transferase, ALAT: alanine amino transferase, BMI: body mass index.
doi:10.1371/journal.pone.0083983.t001
Table 2. Description of patients.
NOR SA
n=43 n=19 p
Sex, males n (%) 28 (65.1%) 9 (47.4%) 0.263 b
Age, years 58.368.3 49.769.4 0.001a
Age at diabetes debut,
years
48.769.1 40.4610.4 0.002a
Diabetes duration, years 9.667.0 9.365.4 0.864a
Diabetes medication, n (%): 0.564b
Lifestyle 6 OAD or GLP-1 26 (60.5%) 10 (52.6%)
Insulin 6 OAD 17 (39.5%) 9 (47.4%)
Diabetes complications,
n (%):
20 (46.5%) 8 (42.1%) 0.788b
Cardiovascular disease 3 (7.0%) 2 (10.5%)
Nephropathy/microalb. 8 (18.6%) 2 (10.5%)
Other 17 (39.5%) 7 (36.8%)
Data are presented as number (percentage) or as mean 6 standard deviation.
p-values from aStudent’s t-test or bChi square test. OAD: oral antidiabetic agent,
GLP-1: Glucagon-like peptid 1 analogue. Microalb.: microalbuminuria. Other
complications include ophthalmopathy, neuropathy, diabetic foot, sexual
dysfunction and periodontal disease. NOR=Nordic, SA = South Asians.
doi:10.1371/journal.pone.0083983.t002
Table 3. Anthropometrical and biochemical characteristics.
NOR SA
n=43 n=19 p
Height, cm 173.668.8 163.468.4 ,0.001
Weight, kg 100.4 [15.0] 79.1 [15.0] ,0.001a
BMI, kg/m2 33.264.7 28.764.0 ,0.001
Waist circumference, cm 115.5 [18.0] 100 [10.6] ,0.001a
Waist/Height ratio 65.567.2 61.266.8 0.033
TBF, % 35.767.2 34.567.6 0.56
Truncal fat, % 40.565.7 40.166.6 0.82
FFM, kg 63.869.7 50.167.7 ,0.001
FM, kg 33.1 [17.1] 25.0 [10.8] ,0.001a
Fasting plasma glucose, mM 9.1 [4.5] 10.7 [6.4] 0.08a
HbA1c, % 7.3 [1.6] 8.5 [1.6] 0.024
a
Fasting insulin, pM 85.5 [99.0] 68.0 [138.0] 0.67a
Fasting C-peptide, pM 1137 [785] 1012 [431] 0.049a
25(OH)vitamin D, nM 40.1610.3 31.5614.0 0.009
Data are presented as mean 6 standard deviation or median [inter-quartile
range]. NOR: Nordic, SA: South Asians, BMI: body mass index, TBF: total body fat,
FFM: fat free mass, FM: fat mass, 25(OH)vitamin D: 25-hydroxyvitamin D. p-
values are from Student’s t-test.
a = Student’s t-test after Log-transformation.
doi:10.1371/journal.pone.0083983.t003
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Indirect Calorimetry
Indirect calorimetry was performed in 38 of the 43 NOR and
14 of the 19 SA patients, using a Jaeger Oxycon Pro (Erich Jaeger,
Viasys Healthcare, Germany) computerized flow-through canopy
gas analyzer system. After a 10-minute adaptation period, expired
and inspired air was continuously sampled and analyzed for O2
and CO2 content during a 30 minute steady state period at the end
of the basal tracer equilibration period and at the end of the
euglycemic clamp. Whole body substrate oxidation was estimated
from the mean values of VO2 and VCO2 measured, and from
measurement of urinary nitrogen (urea). Average basal and insulin
stimulated glucose and lipid oxidation rates were calculated using
Frayn’s equations [10]. Non-oxidative glucose metabolism was
calculated as the difference between total body glucose disposal (as
determined by the euglycemic clamp with tracer dilution method)
and the rate of glucose oxidation (as determined by indirect
calorimetry).
Blood Samples
Full blood glucose was measured by glucose oxidase method
(YSI 2300, Yellow Springs, OH), and plasma glucose was
calculated (full blood glucose61.119). HbA1c was measured by
HPLC on a Tosoh G7 analyser (Tosoh Corp., Tokyo, Japan),
serum insulin and C-peptide were measured using an immuno-
fluorometric assay (DELFIA) from Perkin Elmer Life Sciences
(Wallac Oy, Turku, Finland), 25-hydroxyvitamin D was measured
on a radioimmunoassay (RIA) kit from DiaSorin (Stillwater, MN).
[6,6-2H2]-glucose was measured by LC-MS/MS, via turbulent
flow chromatography (Cohesive technologies RXT1, Franklin,
MA) combined with tandem mass spectrometry (Sciex API3000,
Applied Biosystems, Foster City, CA) as previously described [11],
at the Clinical Metabolomics Core Facility, (Rigshospitalet,
Copenhagen, Denmark). Urinary urea was measured by enzy-
matic-kinetic UV assay on a Roche Modular P analyser.
Statistical Analysis
Data are presented as mean 6 standard deviation or median
[inter-quartile range] unless otherwise specified. We analyzed non-
normally distributed data log-transformed, or using non-paramet-
ric methods, as appropriate. Student’s t tests or Mann Whitney U
tests were used for comparison of continuous variables between
groups, and paired samples t-tests were used for within groups
analysis of change. For comparison of categorical data between
patient groups, the Chi square test for independence was used.
Spearman’s correlation coefficients (rs) were used. One–way
between-groups ANCOVA was performed, with preliminary
checks to ensure no violation of the assumptions of normality,
linearity, homogeneity of variances and homogeneity of regression
slopes. Multiple linear regression analyses were performed, with
log-transformation of parameters when needed, to ensure no
violation of the assumptions of normality, linearity and homosce-
dasticity. In regression analyses NOR=1 and SA=2. A two-sided
p-value ,0.05 was deemed significant, and uncorrected p-values
are presented. Bonferroni-Holm corrections were performed,
showing that p-values ,0.01 remained ,0.05 after correction.
Statistical analyses were performed with SPSS 19.0 for windows
(SPSS Inc., Chicago, IL).
Results
General Description
Anthropometric and biochemical characteristics by ethnic
group are presented in Table 3. The SA subjects were significantly
shorter and leaner than the NOR subjects, but had a higher
median HbA1c, whereas median fasting C-peptide was signifi-
cantly higher in the NOR group. Despite a higher waist
circumference and waist-to-height ratio in the NOR subjects,
the SA still had similar percentage total and truncal fat to the
NOR group. Adjusting for sex and/or age did not change these
results (data not shown).
Endogenous Glucose Production
EGPbasal was significantly higher in the SA than the NOR
group, as shown in Table 4 and Figure 1A. This difference
remained significant after adjustment for possible confounders,
including sex, age, height, weight, BMI, %TBF, FFM, HbA1c,
fasting C-peptide, or fasting plasma glucose (data not shown).
During clamp hyperinsulinemia the EGP was reduced, the ethnic
difference in endogenous glucose production (EGPclamp) was
attenuated, and no longer significant.
EGPclamp was detectable in all patients, ranging from 3.4% to
90.6% of the total glucose disposal rate (TGD), with a median of
25.8%. In an effort to find predictors of EGPclamp variation, we
performed simple correlations between EGPclamp and parameters
which could influence EGPclamp. The following parameters
correlated to EGPclamp with a p-value ,0.1: diabetes duration,
fasting plasma glucose (FPG), se-insulin at end of clamp, fasting se-
C-peptide and HbA1c (Table 5). We then performed an all subsets
multiple regression analysis, using logEGPclamp as dependent
variable. Log FPG was the only significant parameter to remain,
with an unstandardized beta = 0.78, p = 0.003 and an R2 of only
0.15. The separate correlation coefficients in the ethnic subgroups
showed differences: FPG and most of the other parameters
correlated significantly to EGPclamp only in the NOR group. The
correlation between GIR and EGPclamp was neither significant in
the total patient group nor in the two separate ethnic subgroups.
The correlation between TGD and EGPclamp was significant in the
SA subgroup but not the NOR subgroup.
Table 4. Endogenous glucose production, insulin sensitivity
and insulin secretion.
NOR
n=41
SA
n=18 p
EGPbasal mmol/kg
FFM?min
14.4 [6.8] 19.1 [9.1] 0.003
EGPclamp mmol/kg
FFM?min
8.9 [6.7] 10.8 [10.4] 0.216
EGPclamp % % of TGD 24.9 [24.3] 38.7 [27.7] 0.107
GIR mmol/kg
FFM?min
28.9615.8 24.7614.6 0.343
TGD mmol/kg
FFM?min
39.2617.6 39.1620.4 0.990
Se-insulinend clamp pM 1290 [425] 1270 [1087] 0.889
AIRg 0–8 min AUC 0–8 min 124 [275] 220 [302] 0.352
AIRg 0–30 min AUC 0–30 min 1003 [1505] 852 [1452] 0.383
LogAIRg 0–8 min LogAUC 0–8 min 2.1560.52 2.3460.44 0.201
LogAIRg 0–30 min LogAUC 0–30 min 3.0660.36 2.9860.32 0.425
Data are presented as mean 6 standard deviation or median [inter-quartile
range]. p-values from Student’s t-tests or Mann-Whitney U tests as appropriate.
NOR: Nordic, SA: South Asians, EGP: endogenous glucose production, FFM: fat
free mass, TGD: total glucose disposal, GIR: glucose infusion rate, AIRg: acute
insulin response to glucose, AUC: area under the curve (from 0–8 minutes and
0–30 minutes of the intra-venous glucose tolerance test). For LogAIRg 0–8 min
n = 36 NOR and 16 SA, and for LogAIRg0–30 min n = 40 NOR and 17 SA.
doi:10.1371/journal.pone.0083983.t004
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Insulin Sensitivity
There was no significant ethnic difference in insulin sensitivity
expressed as the TGD in mmol/kgFFM?min (Table 4, Figure 1A).
After adjusting TGD for log EGPclamp (beta = 28.4, p = 0.001) and
log waist circumference (beta =2114.7, p = 0.028), in a multiple
regression analysis, ethnicity came closer to significance (be-
ta =29.1, p = 0.111). Further adjusting for age (p = 0.84) or sex
(p = 0.97) was not significant.
Insulin Secretion
All but seven of the 60 subjects where an IVGTT was
performed had some preserved first phase insulin secretion,
(increased incremental AUC0–8), and two thirds of the patients
displayed an AUC0–8.100 pM. Insulin secretion (AIRg) did not
differ significantly between the two ethnicities (Table 4, Figure 1B).
After adjusting for HbA1c in a multiple regression analysis to
account for possible glucose toxicity, there was a non-significant
trend towards higher insulin secretion in the SA group
(beta = 0.30, p = 0.052, model significance: p = 0.030). LogAUC0–
8 was the dependent variable and ethnicity and log HbA1c
(beta =22.27, p = 0.02) were independent variables. Further
adjusting for age (p = 0.39) and sex (p = 0.51) was not statistically
significant. When measured as the AUC0–30, insulin secretion did
not differ between the two ethnic groups, neither before nor after
adjustment for HbA1c, age and/or sex. A longitudinal analysis of
AUC for insulin during the total 30 minutes of IVGTT did not
show any significant ethnic difference either (Figure 1B).
Glucose and Fat Oxidation and Non-oxidative Glucose
Metabolism
Figure 2 displays glucose and fat metabolism in peripheral
tissues in the basal fasting and the hyperinsulinemic clamp state,
measured by indirect calorimetry. Figure 2A demonstrates that
higher endogenous glucose production in SA leads to increases in
both oxidative and non-oxidative metabolism in peripheral tissues.
This figure also demonstrates the higher non-oxidative than
oxidative metabolism in the basal state in both ethnic groups, and
that non-oxidative glucose metabolism increases more than
oxidative in the clamp hyperinsulinemic state in both ethnicities.
Basal fat oxidation measured per kg fat free body mass was
similar in the two ethnic groups (Table 6, Figure 2B). Fat oxidation
decreased during clamp hyperinsulinemia, as glucose metabolism
increased. These changes were similar in the two groups.
Basal and Clamp Energy Expenditure
The mean, unadjusted resting energy expenditure (REE) in kJ/
day, estimated by indirect calorimetry, was higher in the NOR
than in the SA patients (Table 6). However, after adjustment for
FFM, FM, age and sex in a one-way ANCOVA analysis, the
ethnic difference was attenuated, and no longer significant
(p = 0.51), with adjusted mean (SEM) values of 7155 (121) kJ/
day in NOR and 6954 (239) kJ/day in SA patients.
REE correlated highly with basal fat oxidation (rs = 0.48,
p = 0.002 in NOR and 0.64, p = 0.014 in SA patients), but not
with basal glucose oxidation (rs =20.06, p = 0.73, and 20.10,
p = 0.75, respectively), or non-oxidative glucose metabolism
(rs =20.16, p = 0.36, and rs = 0.40, p = 0.16 respectively), although
SAs showed a stronger correlation between REE and non-
oxidative glucose metabolism than the NOR group.
The positive correlation between REE and EGPbasal tended to
be stronger in SA (rs = 0.53, p = 0.051), compared to the NOR
subjects (rs =20.18, p = 0.28). The correlation between EEclamp
and EGPclamp was also stronger in SA (rs =0.50, p = 0.082), than in
NOR subjects (rs =20.06, p = 0.74). Energy expenditure increased
significantly during clamp (EEclamp) in the NOR patients
(p = 0.003), but not in the SA patients (p = 0.28). The respiratory
quotient (RQ) increased significantly from basal to clamp value in
both NOR (p,0.001) and SA subjects (p = 0.008) (Table 6). This
change (DRQ) was similar in the two groups.
Relation between Insulin Sensitivity, Insulin Secretion
and Vitamin D
Median serum 25-hydroxyvitamin D in the SA group was
significantly lower than in the NOR group (table 3). We found no
significant correlations between 25-hydroxyvitamin D levels and
insulin sensitivity or insulin secretion, neither in the two ethnic
groups examined separately, nor in the total cohort.
Discussion
In this study we examined ethnic differences in glucose and fat
metabolism and energy expenditure in basal and clamp hyperin-
sulinemic conditions in subjects with T2D, of SA or NOR
ethnicity, living in Oslo, Norway. We found evidence of ethnic
differences in fasting endogenous glucose production, and
Figure 1. Glucose delivery and insulin secretion during basal and clamp conditions. A) Median [inter-quartile range] values of basal and
clamp glucose delivery per kg fat free mass (FFM), both from endogenous glucose production and exogenous glucose infusion. p-values from Mann-
Whitney U tests. B) Mean (standard error of mean) serum insulin levels during the 30-minute intra-venous glucose tolerance test. NOR=Nordic,
SA= South Asians.
doi:10.1371/journal.pone.0083983.g001
Table 5. Correlations to endogenous glucose production
during clamp.
Total
patients NOR SA
n=57 n=39 n=18
Diabetes duration rs 0.251 0.343 20.058
p 0.059 0.033 0.819
Fasting plasma glucose rs 0.420 0.524 0.057
p 0.001 0.001 0.823
Serum insulin at end of clamp rs 20.295 20.187 20.387
p 0.026 0.254 0.113
Fasting serum C-peptide rs 20.272 20.320 20.034
p 0.040 0.047 0.926
HbA1c rs 0.335 0.338 0.101
p 0.011 0.035 0.689
Exogenous glucose infusion rate rs 20.035 20.116 0.228
p 0.798 0.480 0.363
Total glucose disposal rs 0.318 0.156 0.591
p 0.016 0.342 0.010
Data are presented as Spearman’s correlation coefficients (rs) with
corresponding p-values. Significant correlations in bold. NOR: Nordic, SA: South
Asians.
doi:10.1371/journal.pone.0083983.t005
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indications of possible differences in the choice of substrates for
energy expenditure both in basal and clamp conditions.
The concept of ethnicity and ethnic groups is complex,
consisting of both socio-cultural and biological components that
are not clearly defined [12]. The term South Asian ethnicity is
often used, although the South Asian region is diverse, with several
countries (Pakistan, India, Bangladesh and Sri Lanka), and
differences in culture, religion and diet. In diabetes research,
using the term South Asian can nonetheless be justified, in view of
the fact that the high prevalence of diabetes and increased insulin
resistance is present in the whole region [13], particularly in urban
areas, and also after migration to Western countries [1].
This study shows a significantly higher fasting EGP in SA
compared to NOR patients, which was not explained by any of the
examined possible confounding factors. During clamp hyperinsu-
linemia the EGP was lowered, and the ethnic difference was
attenuated. Even so, EGPclamp was still not negligible, and
constituted almost 40% of TGD in SA and 25% in NOR patients.
Hyperinsulinemia during clamp is often said to suppress EGP
almost entirely [14,15], and euglycemic clamp studies are still
frequently performed without the measurement of endogenous
glucose production [16,17]. However, several authors have
demonstrated that EGPclamp persists [18–20]. We here present
further evidence that EGPclamp can be substantial in type 2
diabetic patients, even with serum insulin concentrations during
clamp as high as 1000–1500 pM. This finding underscores the
importance of controlling for hepatic glucose production during
clamp studies.
Measuring EGP via the isotope tracer dilution method is both
time consuming and costly. In an attempt to find predictors for the
estimation of EGPclamp from variables that are easier to measure,
we looked at a group of variables which correlated with EGPclamp.
Only FPG remained significantly related to EGPclamp in regression
analyses, and it explained only 15% of EGPclamp variation in the
whole patient group. When looking at the correlations in the
separate ethnic subgroups, most variables only correlated signif-
icantly in the NOR group. The exogenous glucose infusion rate
did not correlate to EGPclamp at all. In the SA group, the only
significant correlation was between EGPclamp and TGD, merely
reflecting the high percentage of EGPclamp in TGD in this group.
We therefore suggest that measuring EGPclamp, in addition to the
exogenous glucose infusion rate, is essential for correct estimation
of total glucose disposal rate.
Some ethnic groups residing in tropical climates, including
SA, have previously been shown to have lower REE than
Westerners [21], however, several authors have advocated the
need for adjusting REE for fat free mass (FFM) and fat mass
(FM), as well as age and sex [4,22]. The lower REE in SA is in
this way shown to be due to differences in body composition
and not due to ethnicity per se. We find it to be the case also
in our study. Our two ethnic groups display clear differences in
body composition, and adjusting for these differences, mainly
FFM, attenuates the ethnic difference seen in REE. This,
however brings us back to the complex concept and definition
of ethnicity, whence it can also be argued that lower FFM is an
ethnic characteristic of South Asians. This has been described in
other studies [23,24].
In basal, resting conditions, energy production is for the most
part derived from lipids, and less from carbohydrates [25]. This
is also reflected in our study, by the highly significant
correlation between REE and fat oxidation in both ethnicities.
In the SA subgroup, however, there is also a near-significant
correlation between REE and EGPbasal. This could signify
increased use of carbohydrates as energy substrate in the fasting
state in SA, to such an extent that it becomes important for the
total REE. However, we did not find any ethnic differences in
basal RQ or in DRQ from fasting to clamp hyperinsulinemic
conditions, that would have clearly indicated an ethnic
Figure 2. Glucose and fat metabolism in Nordic and South Asian subjects with type 2 diabetes. A) Glucose metabolism per kg fat free
mass (FFM). Median [inter-quartile range] values of basal and clamp glucose delivery, both from non-oxidative glucose metabolism (NOGM) and
oxidative glucose metabolism (OGM) B) Fat oxidation per kg fat free mass (FFM). Mean (standard error of mean) values in basal and clamp conditions.
NOR=Nordic, SA= South Asians. Comparisons beween ethnic groups are Student’s t-tests or Mann-Whitney U tests as appropriate. Comparisons
between basal and clamp values are paired samples t-tests, after log-transformation where appropriate.
doi:10.1371/journal.pone.0083983.g002
Table 6. Basal and Clamp Indirect Calorimetry.
NOR
n=38
SA
n=14 p
Basal glucose oxidation mmol/kg FFM?min 6.564.5 8.564.0 0.151
Basal non-oxidative glucose consumption mmol/kg FFM?min 9.065.9 12.069.1 0.167
Basal fat oxidation mg/kgFFM?min 1.2460.37 1.1860.36 0.572
Clamp glucose oxidation mmol/kg FFM?min 12.764.6 14.266.7 0.331
Clamp non-oxidative glucose consumption mmol/kg FFM?min 26.3 [17.6] 26.6 [29.5] 0.897
Clamp fat oxidation mg/kgFFM?min 0.8960.38 0.8160.50 0.557
REE kJ/day 746561202 610461214 0.001
EEclamp kJ/day 775061315 626361139 ,0.001
RQbasal 0.7960.05 0.8060.04 0.201
RQclamp 0.8460.05 0.8660.06 0.440
DRQ 0.05260.035 0.05360.062 0.994
Data are presented as mean 6 standard deviation or median [inter-quartile range]. p-values from Student’s t-tests or Mann-Whitney U tests as appropriate. NOR: Nordic,
SA: South Asians, FFM: fat free mass, REE: resting energy expenditure, EEclamp: energy expenditure during clamp, RQ: respiratory quotient, DRQ: change in respiratory
quotient from basal to clamp conditions.
doi:10.1371/journal.pone.0083983.t006
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difference in metabolic flexibility. The values of basal RQ and
DRQ in our subjects were comparable to the group with
diabetes in the recently published study by van de Weijer [26].
In that study, they also demonstrated that insulin stimulated
RQ is mainly dependent on glucose disposal rates, which in our
study are similar in the two groups.
Our NOR participants are significantly more obese than the
SA, which could in part explain why there is no obvious ethnic
difference in TGD. After adjustment for difference in waist
circumference, as well as the endogenous glucose production, the
ethnic difference in TGD came closer to significance.
In our study we found a non-significant trend towards higher
both oxidative and non-oxidative glucose metabolism in SA
compared to NOR subjects in the basal, post-absorptive state.
The total EGPbasal was significantly higher. This points towards
a higher degree of hepatic insulin resistance in SA. One could
speculate that a possible higher basal oxidative glucose
metabolism in muscle, triggered by increased substrate avail-
ability from fasting hyperglycemia, leads to less use of lipids as
energy substrate, again leading to lipid accumulation and
further aggravation of the hepatic insulin resistance, as
described in the metabolic inflexibility hypothesis [3]. In post-
absorptive conditions skeletal muscle contribution to total
metabolism is modest [3]. A possible ethnic difference in
muscle metabolism could thus have been masked.
The hepatic insulin resistance could also initially have been
caused by increased lipid storage in the liver due to adipose tissue
overflow [2]. Percentage truncal fat was similar in our two ethnic
groups, although the NOR group was significantly more obese. In
a previous study we found that even though a group of Pakistani
and Norwegian subjects with T2D had similar abdominal adipose
tissue distribution, the visceral adipose tissue was more metabol-
ically active in the Pakistani subjects (Wium C, Eggesbo HB,
Ueland T et al, 2013, unpublished data). An increased supply of
NEFA from visceral adipose tissue to the liver would, in addition
to the effect of increasing the insulin resistance, constitute a source
of substrate for gluconeogenesis.
Gluconeogenesis is known to be increased in subjects with T2D,
being in large part responsible for the increased post-absorptive
EGP. When using [6,6-2H2] glucose as tracer, Cori cycling is
included in the estimation of the total glucose disposal, and has
been shown to be increased 25% in T2D in general [27]. It is
possible that the increase in non-oxidative glucose metabolism in
SA in large part corresponds to increased Cori cycling, due to
substrate availability through hyperglycemia in tissues, with lactic
acid production in muscle or other tissues by anaerobic glycolysis,
then transport back to the liver and re-use as substrate in
gluconeogenesis, creating a vicious circle.
The data in this study are baseline results from a vitamin D
intervention trial. It was therefore of interest to look for
associations between baseline 25-hydroxyvitamin D levels and
measures of insulin sensitivity and insulin secretion. We found
significantly lower median 25-hydroxyvitamin D levels in the SA
group. Could differences in vitamin D status explain some of the
ethnic differences in glucose metabolism? Several epidemiological
studies have in recent years shown a relationship between vitamin
D and diabetes [28,29], the metabolic syndrome [28], insulin
resistance [30,31], and some studies also with insulin secretion
[32]. However, in most of the published studies that report
significant associations, or an effect of vitamin D intervention, the
primary end points have been surrogate markers based on fasting
blood values, like the HOMA indices [28,33,34]. The few studies
using more sophisticated methods, like OGTT, IVGTT or clamps
have usually not been able to show similar significant relationships
[35–39]. We did not find any association between levels of 25-
hydroxyvitamin D and TGD or AIRg. The question therefore still
remains whether there is a genuine and causal relationship
between vitamin D and diabetes, and we have to await results
from randomised, controlled trials.
A strength of this study was the use of gold standard methods
such as the euglycemic clamp with tracer dilution, coupled with
indirect calorimetry. This enabled us to measure both fasting
endogenous glucose production and insulin sensitivity, as well as
carbohydrate and fat metabolism, both in the basal and
hyperinsulinemic state. To our knowledge, this has not been
reported in SA subjects with T2D previously. The patients were
included by a large variety of approaches, with wide inclusion
criteria, the main restriction being the 25-hydroxyvitamin D levels
#50 nM, with the aim of securing broad representativeness. The
following limitations must be noted: The data presented here are
cross-sectional. No efforts towards matching of the two ethnic
groups at baseline were made. The inclusion of SA patients in the
study proved challenging, hence the SA group was limited in size,
increasing the risk of Type II statistical errors. Further studies in a
larger group of patients, will therefore be necessary to confirm
some of the findings that are still uncertain in our study. We
selected only subjects with low levels of vitamin D, and our results
therefore cannot be generalized to the whole population of
subjects with T2D, although low vitamin D levels are common i
T2D. Nevertheless, we did not find any correlation between 25-
hydroxyvitamin D levels and insulin sensitivity or insulin secretion.
This is an exploratory study, and we have judged it appropriate
not to show p-values corrected for multiple testing. Bonferroni-
Holm corrections were performed, showing that p-values ,0.01
remained significant. However, due to the high risk of missing a
genuine difference that is clinically significant, we still focus on the
non-corrected tests [40]. Hence, there is also a risk of reporting p-
values ,0.05 by chance.
Conclusions
We have demonstrated higher basal EGP in SA patients with
established T2D. Clamp EGP can be substantial in patients with
established T2D, and cannot be estimated from the surrogate
markers measured. We found no ethnic difference in insulin
sensitivity or in first phase insulin secretion. Findings of near
significant correlations between REE, EEclamp and EGP in the SA
group only, might indicate increased post-absorptive glucose
metabolism in the SA group, at the expense of lipid metabolism,
but these results have to be confirmed in larger studies. Finally, we
found no indication of any relation between vitamin D and insulin
sensitivity and secretion.
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